

BMJ Open

Respiratory distress syndrome in moderately late and late preterm Infants and risk of cerebral palsy

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011643
Article Type:	Research
Date Submitted by the Author:	23-Feb-2016
Complete List of Authors:	Thygesen, Sandra; Aarhus Universitetshospital, Department of Clinical Epidemiology Olsen, Morten; Aarhus University, Department of Clinical Epidemiology Ostergaard, John; Aarhus Universitetshospital, Department of Pediatrics Sørensen, Henrik T.; Aarhus University Hospital, Department of Clinical Epidemiology; Stanford University, Departments of Health Research and Policy (Epidemiology)
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Paediatrics, Neurology, Respiratory medicine
Keywords:	EPIDEMIOLOGY, respiratory distress syndrome, cerebral palsy, neurodevelopmental disorder, cohort study, PERINATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Respiratory distress syndrome in moderately late and late preterm Infants and risk of**
5
6 **cerebral palsy**
7
8

9 Sandra Kruchov Thygesen, Morten Olsen, John R. Østergaard, Henrik Toft Sørensen
10

11
12 **Affiliations:**
13

14
15 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
16 Denmark
17 Sandra Kruchov Thygesen
18 MD
19

20
21 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
22 Denmark
23 Morten Olsen
24 Associate professor

25
26 Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200 Aarhus N,
27 Denmark
28 John R Østergaard
29 Professor

30
31 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
32 Denmark and
33 Departments of Health Research and Policy (Epidemiology), Stanford University, 259 Campus Drive,
34 Stanford, CA 94305, United States
35 Henrik Toft Sørensen
36 Professor

37
38 **Keywords:** Epidemiology, cohort study, pediatrics, neurology, pulmonary medicine

39
40 **Corresponding Author:** Sandra Kruchov Thygesen, st@clin.au.dk, phone: + 45 8716 8063

41
42 **Word count:** abstract 317 + article 2,510

43
44 **Number of figures:** 1

45
46 **Number of tables:** 3

47
48 **Number of supplementary file:** 1 (appendix)

49
50 **Number of references:** 35
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Infant respiratory distress syndrome (IRDS) is a known risk factor for intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia. These lesions are known to increase the risk of cerebral palsy (CP). Thus, we wanted to examine the long-term risk of CP following IRDS in moderately late and late preterm infants.

Design: Population-based cohort study.

Setting: All hospitals in Denmark.

Participants: We used nationwide medical registries to identify a cohort of all moderately and late preterm infants (defined as birth during 32-36 full gestational weeks) born in Denmark in 1997-2007 with and without hospital diagnosed IRDS.

Main outcomes measures: We followed study subjects from birth until first diagnosis of CP, emigration, death, or end of follow-up in 2014. We computed the cumulative incidence of CP before age 8 years and used Cox's regression analysis to compute hazard ratios of IRDS, comparing children with IRDS to those without. Hazard ratios were adjusted for multiple covariates.

Results: We identified 39,420 moderately late and late preterm infants, of whom 2,255 (5.7%) had IRDS. The cumulative incidence of CP was 1.9% in infants with IRDS and 0.5% in the comparison cohort. The adjusted hazard ratio of CP was 2.0 [95% confidence interval (CI): 1.4-2.9]. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by ICH/IVH. The hazard ratio of CP in infants with IRDS that was not accompanied by ICH/IVH was 1.8 (95% CI: 1.3-2.7). After restriction to children without diagnoses of perinatal breathing disorders other than IRDS, congenital heart disease and viral or bacterial infections occurring within 4 days of birth, the overall adjusted hazard ratio was 2.1 (95% CI: 1.4-3.1).

1
2
3
4 **Conclusion:** The risk of CP was increased in moderately late and late preterm infants with IRDS
5
6 compared to infants without IRDS born during the same gestational weeks.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- A strength of this study includes the nationwide cohort study design with virtually complete follow-up, minimizing the risk of selection bias.
- To our knowledge, this is the first study to specifically determine the association between infant respiratory distress syndrome and cerebral palsy utilizing multivariate analysis, and as such, the validity of the estimates presented is unknown.
- Even though this study is one of the largest examining a potential association between infant respiratory distress syndrome and cerebral palsy, it still does not clarify the specific causes leading to increased risk of cerebral palsy.

Introduction

Increasing preterm birth rates over the last few decades have kept the overall incidence of infant respiratory distress syndrome (IRDS) high.¹⁻³ Infant respiratory distress syndrome decreases with increasing gestational age and has a prevalence of about 30% after 32 weeks of gestation.⁴⁻⁶ The condition is caused by lack of surfactant in the lungs, which leads to atelectasis, decreased gas exchange, and hypoxia. Potential complications of IRDS include intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia (PVL).^{7,8} Studies have reported increased risk of neurodevelopmental impairments, such as neurocognitive and school performance outcomes as well as attention deficit hyperactivity disorder (ADHD) in preterm children with subsequent ischemic-hypoxic conditions, including IRDS.^{9,10}

Cerebral palsy (CP) is the most common cause of severe disabilities in early childhood.¹¹ The core symptom of CP is disorder of movement and/or posture, but is often accompanied by other neurodevelopmental disorders or sensory problems, such as disturbances of sensation, cognition, communication, perception, behavior and/or seizure disorders.¹² The disorder has a multifactorial and poorly understood etiology. The most important risk factor for CP is preterm birth, observed in about 28%–35% of all children with CP.^{13,14} Major lesions that contribute to CP include ICH/IVH and PVL.^{7,15,16}

Few data exist on the long term prognosis following IRDS. A few case-control studies have reported indications of an association between IRDS and CP.¹⁷⁻¹⁹ However, these studies are limited by small sample sizes and lack of absolute risk estimates. In the present study, we therefore examined the association between IRDS and CP in a nationwide follow-up study of children born moderately and late preterm.

Methods

Setting and data linkage

We conducted this cohort study using population-based medical databases covering the entire country of Denmark. Linkage between databases was possible through the Civil Registration System (CRS), which has kept electronic records of birth date, date of emigration, and date of death since 1968.²⁰ At birth or upon immigration, all Danish residents are assigned a unique Civil Personal Registration (CPR) number that is used in all public Danish registries. The Danish National Health Service provides free tax-supported health care to the country's 5.6 million citizens.

Study Cohort

Our cohort was identified using the Danish Medical Birth Registry, which contains information on all births in Denmark since 1973. We identified all infants born alive in Denmark from January 1, 1997 to December 31, 2007 (approximately 710,000 infants)^{21, 22} and then restricted our cohort to moderately late and late preterm infants (defined as birth between 32 and 36 full weeks). Adequate representation of children both with and without IRDS is available during these gestational weeks.

Infant respiratory distress syndrome

We identified all children diagnosed with IRDS (exposed children) in the Danish National Patient Registry (DNPR). The DNPR contains data on all non-psychiatric hospital admissions in the country since 1977 and on outpatient clinic and emergency room visits since 1995.^{23, 24} Data include dates of admission and discharge, surgical procedure(s) performed, and one primary diagnosis and up to 19 secondary diagnoses coded by the discharging physician according to the *International*

1
2
3
4 *Classification of Diseases, Eighth Edition (ICD-8)* until the end of 1993 and the *Tenth Edition*
5
6 (ICD-10) thereafter.
7

8 9 ***Cerebral palsy***

10
11
12 Children diagnosed with CP were identified from the Danish National Cerebral Palsy Registry
13 (DNCPR). Prerequisites for inclusion in this Registry are a prenatal or perinatal aetiology (events
14 occurring within 28 days of birth.
15
16

17
18
19 All children included in the Registry had their diagnosis externally validated by a child neurologist
20 at the age of 4-5 years, based on review of clinical findings recorded in the medical files. While the
21 Registry includes data on prenatally and perinatally acquired cases of CP since 1950, it became
22 nationwide only in 1995. NCRP is assumed to cover > 85 % of the children with CP in Denmark.²⁵
23
24 Registry data include subtype and degree of CP,¹¹ developmental quotient (DQ: <50, 50-85, >85),
25
26 motor handicap measured by the Gross Motor Function Classification System (GMFCS, 0-4)
27
28 (though only complete until birth year 2003), accompanying neurological diseases, and orthopedic
29
30 surgeries. Results of ultrasound and CT scans of the brain and evaluation of timing of brain damage
31
32 are available.²⁵ The GMFCS is a tool used to measure gross motor skills in children with CP. The
33
34 classification system ranges from level 1 (walking with no support) up to level 5
35
36 (immobile/impaired in all areas of motor function).²⁶ We obtained the following study outcomes
37
38 from the Registry: overall diagnosis of CP, subtypes of unilateral and bilateral spastic CP, motor
39
40 handicap degree (GMFCS levels 1-2, 3, and 4-5), and DQ (<50, 50-85, and >85).
41
42
43
44
45
46
47
48

49 ***Covariates***

50
51
52 We obtained information from the Danish Medical Birth Registry for the entire cohort on
53
54 gestational age at birth, 5-minute Apgar score, multiplicity, maternal age, and self-reported maternal
55
56 smoking during pregnancy.²² We used data from the DNPR to ascertain the distribution of
57
58
59
60

1
2
3
4 complications in children with and without IRDS, including bronchopulmonary dysplasia,
5
6 ICH/IVH, necrotizing enterocolitis, and patent ductus arteriosus (Appendix A). Congenital
7
8 malformations are associated with increased risk of CP and also may be associated with IRDS. We
9
10 therefore ascertained from the DNPR all diagnoses of congenital malformations detected during the
11
12 first year of life.

13
14
15 A subgroup of children may have had other conditions within 4 days of birth whose symptoms
16
17 potentially overlapped with IRDS, leading to misdiagnosis of IRDS. These diseases include
18
19 perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and bacterial
20
21 infections. We identified these conditions from the DNPR. (Appendix A)
22
23

24 25 *Statistical analysis*

26
27
28 We followed all children in the study cohort from date of birth until the date of the first diagnosis of
29
30 CP, emigration, death, or December 31, 2014, whichever came first. We computed the cumulative
31
32 incidence of CP before 8 years of age with death as a competing risk.²⁷ In a sub-analysis, sub-types
33
34 of CP were analyzed as separate outcomes (unilateral and bilateral spastic CP), as well as motor
35
36 handicap degree (GMFCS 1-2, 3, and 4-5) (until birth year 2003), and developmental quotient
37
38 (<50, 50-85, and >85).
39

40
41
42 We used Cox proportional hazard regression to estimate unadjusted and adjusted hazard ratios
43
44 (HRs) for CP among children with IRDS compared to children without IRDS. The analyses were
45
46 adjusted for gestational age (32, 33, 34, 35, and 36 weeks of gestation), birth year (1997-1999,
47
48 2000-2002, 2003-2005, and 2006-2007), gender, multiplicity (singleton/twins), major
49
50 malformations, and maternal age (<35 and \geq 35 years of age). The assumptions of proportional
51
52 hazards were all verified graphically. We considered a low 5-minute Apgar score as a causal
53
54 intermediate step between IRDS and CP, and thus did not include this covariate as a confounder in
55
56
57
58
59
60

1
2
3
4 the adjusted analyses. However, we did include 5-minute Apgar score in the regression model in a
5
6 sub-analysis.
7
8

9 We stratified the analyses on gestational age (birth at 32, 33, 34, and 35-36 full weeks), birth year
10
11 (1997-2002, 2003-2007), gender, multiplicity, 5-minute Apgar score (0-6, 7-8, 9-10, missing), and
12
13 maternal age (<35 and ≥35 years of age) and calculated 95% confidence intervals (CIs).
14

15 Intracerebral/intraventricular hemorrhage is a known complication of IRDS and an important risk
16
17 factor for CP. We therefore repeated the analyses for children with IRDS *and* IVH/ICH within 30
18
19 days of birth and children with IRDS *and no* IVH/ICH.
20
21

22
23 Perinatal diseases may be misinterpreted as IRDS because of overlapping clinical symptoms. Such
24
25 perinatal disorders include perinatal breathing disorders other than IRDS, congenital heart diseases,
26
27 and viral and bacterial infections. Thus, in a sensitivity analysis, we restricted the IRDS cohort to
28
29 new-borns *with no* other perinatal disorders occurring within 4 days of birth.
30
31

32
33 All analyses were performed using the STATA 13.1 package (StataCorp LP, College Station, TX,
34
35 USA). The study was approved by the Danish Protection Agency (record number: 2014-41-3183)
36
37 and did not require informed consent.
38
39

40 ***Patient involvement***

41
42 No patients were involved in setting the research question or the outcome measures, nor were they
43
44 involved in developing plans for design or implementation of the study. No patients were asked to
45
46 advise on interpretation or writing up of results. There are no plans to disseminate the results of the
47
48 research to study participants or the relevant patient community.
49
50
51

52 53 54 55 56 **Results**

1
2
3
4 From the Danish Medical Birth Registry, we identified 39,420 children born moderately and late
5 preterm between 1997 and 2007. Of these, 2,255 (5.7%) were diagnosed with IRDS.
6
7

8 Intracerebral/intraventricular haemorrhage (2%) was more common in the IRDS cohort compared
9 to comparison cohort (0.3%). Having another perinatal disorder occurring within four days of birth,
10 including perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and
11 bacterial infection were more prevalent in the children with IRDS (30%) compared to children
12 without IRDS (18%). (Table 1)
13
14
15
16
17
18
19

20 The cumulative incidence of CP before 8 years of age was 1.9 (95% CI: 1.4-2.5) in children with
21 IRDS and 0.5 (95% CI: 0.4-0.6) in children without IRDS. The overall crude HR for CP in children
22 with IRDS compared to children without IRDS was 4.0 (95% CI: 2.9-5.6). After adjusting for
23 gestational age, birth year, gender, multiplicity, major malformations, and maternal age, the HR was
24 2.0 (95% CI: 1.4-2.9). (Table 2)
25
26
27
28
29
30
31

32 When we stratified the analysis by gestational age, we found an increased risk of CP across all
33 strata in children with IRDS compared to children without IRDS. As well, we found no substantial
34 variation in the increased risk of CP in children with IRDS across categories of gender, year of
35 birth, multiplicity, 5-minute Apgar score, and maternal age, although these estimates were less
36 precise. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by
37 ICH/IVH and 1.8 (95% CI: 1.3-2.7) in children with IRDS without ICH/IVH as a complication.
38
39
40
41
42
43
44
45

46 Including 5-minute Apgar score as a potential confounder in the regression model did not change
47 our estimates substantially. When restricting to children diagnosed with IRDS *and no* other relevant
48 diagnoses occurring within 4 days of birth (i.e. perinatal breathing disorders other than IRDS,
49 congenital heart diseases, and viral and bacterial infections), the overall adjusted HR was 2.1 (95%
50 CI: 1.4-3.1).
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The most common subtype of CP was unilateral and bilateral spastic CP. (Data not shown) For
5
6 children diagnosed with IRDS, we found a HR of 1.5 (95% CI: 0.8-2.9) for unilateral spastic CP
7
8 and 2.2 (95% CI: 1.4-3.4) for bilateral spastic CP. The HR was 1.9 (95% CI: 1.1-3.4) for CP with a
9
10 normal DQ (above 85), 1.7 (95% CI: 0.9-3.1) for a DQ between 50 and 85, and 2.9 (95% CI: 1.4-
11
12 6.1) for a DQ below 50. (Table 3)

13
14
15
16 In children with IRDS born during 1997-2003, the HR was 2.2 (95% CI: 1.3-3.9) for a mild degree
17
18 of motor handicap (GMFCS 1-2) and 2.5 (95% CI: 1.3-4.7) for a severe degree of motor handicap
19
20 (GMFCS 4-5). (Table 3)

21 22 23 24 25 26 **Discussion**

27
28
29 We found an increased risk of CP associated with IRDS in children born moderately late and late
30
31 preterm. To our knowledge, this is the first study to examine the risk of CP following IRDS.

32
33
34
35 Other studies have shown increased risk of neurodevelopmental impairments, defined by
36
37 psychomotor development and school readiness, in preterm children with IRDS.^{9, 10, 28, 29} Studies
38
39 have looked at possible causes or predictors of cerebral palsy in different settings and found modest
40
41 associations. In an Australian case-control study, Blair et al. reported an odds ratio of CP of 2.3
42
43 (95% CI: 1.3-4.3); and in another case-control study from Western Australia, Dite et al. found an
44
45 odds ratio of 9.4 (95% CI: 1.8-48) in children diagnosed with IRDS. However; even though they
46
47 reported increased risk estimates of CP in children with IRDS, the estimates were based on
48
49 univariate analyses in relatively small study populations. Thus, potential confounders were not
50
51 taken into consideration and no absolute measures were available.¹⁷⁻¹⁹ In a cohort study, Hirvonen
52
53 et al. found a negative association between IRDS and CP in late preterm infants. However,
54
55 apparently the multivariate model included intermediate steps between IRDS and CP in terms of
56
57
58
59
60

1
2
3
4 mechanical ventilator treatment and intracranial hemorrhage. Furthermore, the analysis was not
5
6 based on time-to-event methods, but based on logistic regression.³⁰ This may have explained the
7
8 differences between their results and ours.
9

10
11 Through data linkage performed by the Danish Civil Registration System, this population-based
12
13 study had virtually complete follow-up for death, emigration, and hospital admissions, minimizing
14
15 the risk of selection bias. We previously reported a positive predictive value of 89% (95% CI: 75%–
16
17 96%) for children with IRDS born between 32 and 36 weeks of gestation in the DNPR.³¹ In this
18
19 study, IRDS was based exclusively on clinical symptoms, as x-rays were only used infrequently
20
21 early in the study period. Thus, in a sensitivity analysis, we redefined our exposure of children with
22
23 IRDS to only those having IRDS with no other perinatal disorders occurring within 4 days of birth.
24
25 Our estimates were virtually unchanged in this analysis. Because the Cerebral Palsy Registry is a
26
27 clinical database based on specific inclusion criteria including thorough medical record review of
28
29 all children with CP in Denmark, we expect the positive predictive value of the CP diagnosis to be
30
31 close to 100%. A previous validation study of the NCPR through the DNPR reported its
32
33 completeness to be 85%.²⁵ As any misclassification is not likely associated with IRDS, such non-
34
35 differential bias would eventually lead to an underestimation of the association between IRDS and
36
37 CP.
38
39
40
41
42

43 One of the strongest risk factors for development of CP is known to be low gestational age,^{32, 33}
44
45 which is also the strongest risk factor for IRDS. For this reason, we stratified our analyses on
46
47 gestational age to ensure that any increased risk of CP in children with IRDS was not masked by
48
49 this association. After taking this precaution, we still found an increased risk of CP among children
50
51 born during gestational weeks 32 to 34. Only a few children diagnosed with CP were born during
52
53 35 and 36 weeks of gestation, which made calculations of the HR imprecise.
54
55
56
57
58
59
60

1
2
3
4 To study a rather seldom disease like CP large study populations are required, especially when the
5
6 study sample is restricted to children born at 32-36 gestational weeks. For this reason, we only were
7
8 able to present overall estimates in our analyses of subtypes of CP, degree of motor handicap, and
9
10 DQ. These estimates were all increased throughout all levels of CP severity.

11
12
13
14 Even though this study is among the largest studies examining a potential association between
15
16 IRDS and CP by using data from nationwide databases on preterm infants, it still does not clarify
17
18 the specific causes of the increased risk of CP. We found a twelve-fold increase of CP in children
19
20 with IRDS and ICH/IVH compared to our control population. This suggests an important role of
21
22 ICH/IVH in the pathogenesis.^{15, 34, 35}
23
24

25
26 Infant respiratory distress syndrome potentially could be a surrogate for another unknown medical
27
28 condition. However, recognition of an early predictor of increased future CP risk could still be
29
30 helpful when planning follow-up and/or intervention strategies in children born preterm.
31
32
33
34
35

36 **Conclusion**

37
38
39 We found that the risk of CP was twice as high in moderately late and late preterm infants with
40
41 IRDS compared to infants without IRDS born during the same gestational weeks. Although a
42
43 twelve-fold increased risk of CP was found in children with IRDS and ICH/IVH, the increased risk
44
45 was also present in infants without ICH/IVH.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Copyright Licence:** The Corresponding Author has the right to grant on behalf of all authors and
5 does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

perpetuity, in all forms, formats and media (whether known now or created in the future), to i)
publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
other languages, create adaptations, reprints, include within collections and create summaries,
extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the
Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic
links from the Contribution to third party material where-ever it may be located; and, vi) licence
any third party to do any or all of the above.

Contributor's Statement: SKT conceptualized and designed the study, acquired the data, carried
out the analyses, drafted the initial manuscript, reviewed and revised the manuscript, and approved
the final manuscript as submitted. MO, JRO, and HTS conceptualized and designed the study,
supervised the data interpretation, critically reviewed and revised the manuscript for important
intellectual content, and approved the final manuscript as submitted. MO helped to acquire the data
and extract the raw data, critically supervised/reviewed the data analyses and reviewed the data
interpretation, revised the manuscript, and approved the final manuscript as submitted.

Funding: This study was supported by grants from the Clinical Epidemiological Research
Foundation ('Klinisk Epidemiologisk Forskningsfond'), Denmark (HTS), and the Program for
Clinical Research Infrastructure (PROCRIN) established by the Lundbeck and the Novo Nordisk
Foundations (HTS). The funding agencies had no role in the design of the study; the collection,

1
2
3
4 analysis, and interpretation of the data; the writing of the article; or the decision to submit the article
5
6 for publication.
7
8
9

10
11
12 **Competing risk declaration:** All authors have completed the Unified Competing Interest form at
13 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
14
15 declare: no support from any organisation for the submitted work; no financial relationships with
16
17 any organisations that might have an interest in the submitted work in the previous three years, and
18
19 no other relationships or activities that could appear to have influenced the submitted work
20
21
22
23
24
25
26

27 **Ethical approval:** Not needed.
28
29
30
31
32

33 **Author Statement:** All authors, external and internal, had full access to all of the data (including
34
35 statistical reports and tables) in the study and can take responsibility for the integrity of the data and
36
37 the accuracy of the data analysis.
38
39
40
41
42
43

44 **Transparency declaration:** SKT affirms that the study hypothesis arose before inspection of the
45
46 data and that the manuscript is an honest, accurate, and transparent account of the study being
47
48 reported; that no important aspects of the study have been omitted; and that any discrepancies from
49
50 the study as planned have been explained.
51
52
53
54
55

56 **Data sharing:** No additional data available.
57
58
59
60

References

1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet*. 2012;379:2162-72.
2. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. *Lancet*. 2008;371:75-84.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet*. 2008;371:261-9.
4. Robertson PA, Sniderman SH, Laros RK, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. *Am J Obstet Gynecol*. 1992;166:1629,41; discussion 1641-5.
5. Koivisto M, Marttila R, Kurkinen-Raty M, et al. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990s: a population-based survey. *Acta Paediatr*. 2004;93:177-84.
6. Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. *Biol Neonate*. 1998;74:7-15.
7. Kinney HC. The Near-Term (Late Preterm) Human Brain and Risk for Periventricular Leukomalacia: A Review. *Semin Perinatol*. 2006;30:81-8.

- 1
2
3
4 8. Sun H, Xu F, Xiong H, et al. Characteristics of respiratory distress syndrome in infants of
5
6 different gestational ages. *Lung*. 2013;191:425-33.
7
8
- 9
10 9. McGrath MM, Sullivan MC, Lester BM, et al. Longitudinal Neurologic Follow-Up in Neonatal
11
12 Intensive Care Unit Survivors with Various Neonatal Morbidities. *Pediatrics*. 2000;106:1397.
13
14
- 15 10. Getahun D, Rhoads GG, Demissie K, et al. In utero exposure to ischemic-hypoxic conditions
16
17 and attention-deficit/hyperactivity disorder. *Pediatrics*. 2013;131:e53-61.
18
19
- 20 11. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a
21
22 collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe
23
24 (SCPE). *Dev Med Child Neurol*. 2000;42:816-24.
25
26
- 27 12. Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral
28
29 palsy, April 2005. *Dev Med Child Neurol*. 2005;47:571-6.
30
31
- 32 13. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of
33
34 genetic variants. *Am J Obstet Gynecol*. 2015;.
35
36
- 37 14. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. *Best Pract Res Clin Obstet*
38
39 *Gynaecol*. 2004;18:425-36.
40
41
- 42 15. Futagi Y, Toribe Y, Ogawa K, et al. Neurodevelopmental Outcome in Children With
43
44 Intraventricular Hemorrhage. *Pediatr Neurol*. 2006;34:219-24.
45
46
- 47 16. Blair E, Stanley F. Aetiological pathways to spastic cerebral palsy. *Paediatr Perinat Epidemiol*.
48
49 1993;7:302-17.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Stelmach T, Pisarev H, Talvik T. Ante- and perinatal factors for cerebral palsy: case-control
5 study in Estonia. *J Child Neurol*. 2005;20:654-60.
6
7
8
9
10 18. Dite GS, Bell R, Reddihough DS, et al. Antenatal and perinatal antecedents of moderate and
11 severe spastic cerebral palsy. *Aust N Z J Obstet Gynaecol*. 1998;38:377-83.
12
13
14
15 19. Blair E, Stanley F. When can cerebral palsy be prevented? The generation of causal hypotheses
16 by multivariate analysis of a case-control study. *Paediatr Perinat Epidemiol*. 1993;7:272-301.
17
18
19
20 20. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in
21 epidemiology. *Eur J Epidemiol*. 2014;29:541-9.
22
23
24
25
26 21. Kristensen J, Langhoff-Roos J, Skovgaard LT, et al. Validation of the Danish Birth
27 Registration. *J Clin Epidemiol*. 1996;49:893-7.
28
29
30
31
32 22. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull*. 1998;45:320-3.
33
34
35
36 23. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public*
37 *Health*. 2011;39:30-3.
38
39
40
41 24. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable
42 source of data for modern health sciences. *Dan Med Bull*. 1999;46:263-8.
43
44
45
46 25. Topp M, Langhoff-Roos J, Uldall P. Validation of a cerebral palsy register. *J Clin Epidemiol*.
47 1997;50:1017-23.
48
49
50
51
52 26. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify
53 gross motor function in children with cerebral palsy. *Dev Med Child Neurol*. 1997;39:214-23.
54
55
56
57
58
59
60

- 1
2
3
4 27. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of
5 competing risks: new representations of old estimators. *Stat Med*. 1999;18:695-706.
6
7
8
9
10 28. Piekkala P, Kero P, Sillanpaa M, et al. Growth and development of infants surviving respiratory
11 distress syndrome: a 2-year follow-up. *Pediatrics*. 1987;79:529-37.
12
13
14
15 29. Patrianakos-Hoobler AI, Msall ME, Marks JD, et al. Risk factors affecting school readiness in
16 premature infants with respiratory distress syndrome. *Pediatrics*. 2009;124:258-67.
17
18
19
20
21 30. Hirvonen M, Ojala R, Korhonen P, et al. Cerebral palsy among children born moderately and
22 late preterm. *Pediatrics*. 2014;134:e1584-93.
23
24
25
26 31. Thygesen SK, Olsen M, Christian FC. Positive predictive value of the infant respiratory distress
27 syndrome diagnosis in the Danish National Patient Registry. *Clin Epidemiol*. 2013;5:295-8.
28
29
30
31
32 32. Sukhov A, Wu Y, Xing G, et al. Risk factors associated with cerebral palsy in preterm infants. *J*
33 *Matern -Fetal Neonatal Med*. 2012;25:53-7.
34
35
36
37 33. Topp M, Langhoff-Roos J, Uldall P. Preterm birth and cerebral palsy. Predictive value of
38 pregnancy complications, mode of delivery, and Apgar scores. *Acta Obstet Gynecol Scand*.
39 1997;76:843-8.
40
41
42
43
44 34. Harcke Jr. HT, Naeye RL, Storch A, et al. Perinatal cerebral intraventricular hemorrhage. *J*
45 *Pediatr*. 1972;80:37-42.
46
47
48
49
50 35. Berg B. Neurology of the Newborn, 4th Edition, by J.J. Volpe. *Muscle Nerve*. 2001;24:1099-
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legend:**
5

6 **Figure 1.** Cumulative incidence of cerebral palsy in 24,728 children with and without infant
7 respiratory distress syndrome (IRDS) in Denmark during 1997-2003.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of 39,420 infants born during 32–36 weeks of gestation with and without infant respiratory distress syndrome (IRDS), between January 1, 1997 and December 31, 2007 in Denmark.

	IRDS, n (%)	No IRDS, n (%)
All	2,255 (100.0)	37,165 (100.0)
Gestational age (week of gestation)		
32	602 (26.7)	2,058 (5.5)
33	545 (24.2)	3,313 (8.9)
34	526 (23.3)	5,652 (15.2)
35	346 (15.3)	9,156 (24.6)
36	236 (10.5)	16,986 (45.7)
Birth year		
1997-1999	534 (23.7)	9,379 (25.2)
2000-2002	602 (26.7)	10,443 (28.1)
2003-2005	696 (30.9)	10,433 (28.1)
2006-2007	423 (18.8)	6,910 (18.6)
Gender		
Female	897 (39.8)	17,184 (46.2)
Male	1,358 (60.2)	19,981 (53.8)
Apgar score at 5 minutes		
Low (0-6)	111 (4.9)	646 (1.7)
Intermediate (7-8)	271 (12.0)	1,824 (4.9)
Normal (9-10)	1,816 (80.5)	33,974 (91.4)
Missing	57 (2.5)	721 (1.9)
Multiplicity		
Singleton	1,644 (72.9)	27,438 (73.8)
Twin	611 (27.1)	9,727 (26.2)
Epilepsy		
	53 (2.4)	590 (1.6)
Major malformation (<1 year)		
	217 (9.6)	2,525 (6.8)
Mother's age at delivery		
<18 years	5 (0.2)	130 (0.4)
18-34 years	1,807 (80.1)	30,131 (81.1)
≥35 years	443 (19.7)	6,903 (18.6)
Missing	0 (0.0)	1 (0.0)
Maternal smoking status		

Non Smoker/former smoker	1,689 (74.9)	26,487 (71.3)
Smoker	403 (17.9)	8,433 (22.7)
Missing	163 (7.2)	2,245 (6.0)
Bronchopulmonary dysplasia (BPD) (<1 year)		
Yes	22 (1.0)	16 (0.1)
Intracerebral/intraventricular hemorrhage (ICH/IVH) (<30 days)		
Yes	46 (2.0)	121 (0.3)
Necrotizing enterocolitis (NEC) (<30 days)		
Yes	20 (0.9)	59 (0.2)
Patent ductus arteriosus (PDA) (<30 days)		
Yes	77 (3.4)	239 (0.6)
Other diseases*		
Yes	682 (30.2)	6,641 (17.9)

*Other diseases whose symptoms may overlap with those of IRDS, occurring within 4 days of birth (perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and bacterial infections).

Table 2. Hazard ratios of cerebral palsy (CP) by age 8 among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark. (N=39,410)

	Number of children with CP		8-year cumulative incidence, % (95% confidence interval (CI))		Crude hazard ratio (95% CI)	Adjusted hazard ratio* (95% CI)
	Children with IRDS	Children without IRDS	Children with IRDS	Children without IRDS		
Overall	42	178	1.9 (1.4-2.5)	0.5 (0.4-0.6)	4.0 (2.9-5.6)	2.0 (1.4-2.9)
Gestational age						
32 weeks of gestation	21	31	3.5 (2.2-5.2)	1.5 (1.1-2.1)	2.3 (1.3-4.0)	2.4 (1.4-4.2)
33 weeks of gestation	11	44	2.0 (1.1-3.5)	1.3 (1.0-1.7)	1.6 (0.8-3.1)	1.6 (0.8-3.1)
34 weeks of gestation	7	30	1.4 (0.6-2.7)	0.5 (0.4-0.8)	2.5 (1.1-5.8)	2.5 (1.1-5.8)
[35-36] weeks of gestation	3	73	0.5 (0.1-1.4)	0.3 (0.2-0.4)	1.9 (0.6-6.1)	1.7 (0.5-5.5)
Calendar year						
[1997-2002]	28	105	2.5 (1.7-3.5)	0.5 (0.4-0.6)	4.8 (3.2-7.3)	2.4 (1.5-3.7)
[2003-2007]	14	73	1.3 (0.7-2.1)	0.4 (0.3-0.5)	3.1 (1.7-5.4)	1.4 (0.8-2.6)
Gender						
Female	14	76	1.6 (0.9-2.6)	0.4 (0.4-0.6)	3.6 (2.1-6.4)	1.7 (0.9-3.1)
Male	28	102	2.1 (1.4-3.0)	0.5 (0.4-0.6)	4.2 (2.7-6.3)	2.2 (1.4-3.4)
Apgar score at 5 minutes						
Low (0-6)	4	10	3.7 (1.2-8.5)	1.6 (0.8-2.8)	2.1 (0.7-6.8)	2.2 (0.7-7.7)
Intermediate (7-8)	7	31	2.6 (1.2-5.0)	1.7 (1.2-2.4)	1.6 (0.7-3.5)	1.2 (0.5-2.8)
Normal (9-10)	28	131	1.6 (1.1-2.2)	0.4 (0.3-0.5)	4.1 (2.7-6.2)	1.9 (1.2-2.9)
Missing	3	6	5.3 (1.4-13)	0.8 (0.4-1.8)	6.6 (1.6-26)	6.0 (1.0-35)
Multiplicity						
Singleton	29	129	1.8 (1.2-2.5)	0.5 (0.4-0.6)	3.9 (2.6-5.8)	2.0 (1.3-3.1)
Twin	13	49	2.1 (1.2-3.5)	0.5 (0.4-0.7)	4.3 (2.3-7.9)	1.9 (1.0-3.6)

Maternal age						
Younger than 35 years of age	31	138	1.7 (1.2-2.4)	0.5 (0.4-0.5)	3.9 (2.6-5.7)	1.9 (1.3-2.9)
35 years of age or older	11	40	2.5 (1.3-4.3)	0.6 (0.4-0.8)	4.4 (2.3-8.6)	2.3 (1.1-4.8)

*Adjusted for sex, gestational age, infant's birth year, multiplicity, major malformations, and maternal age.

For peer review only


Table 3. Characteristics of 148 infants with cerebral palsy (CP) born during 32-36 weeks of gestation with and without infant respiratory distress syndrome (IRDS), 1997-2007, Denmark.

	Number of children with CP		Crude hazard ratio (95% CI)*	Adjusted hazard ratio (95% CI)
	Children with IRDS	Children without IRDS		
Sub-type				
Unilateral spastic CP	12	74	2.7 (1.5-5.0)	1.5 (0.8-2.9)
Bilateral spastic CP	26	87	5.1 (3.3-7.9)	2.2 (1.4-3.4)
Motor Handicap [1997-2003]				
GMFCS [†] 1-2	16	71	4.0 (2.3-6.8)	2.2 (1.3-3.9)
GMFCS 3	1	4	4.4 (0.5-39)	2.2 (0.2-21)
GMFCS 4-5	4	70	6.1 (3.3-11)	2.5 (1.3-4.7)
Developmental Quotient (DQ)				
DQ <50	11	33	5.6 (2.8-11)	2.9 (1.4-6.1)
DQ 50-85	14	60	3.9 (2.2-7.0)	1.7 (0.9-3.1)
DQ >85	17	80	3.6 (2.1-6.1)	1.9 (1.1-3.4)

*Confidence interval

[†]Gross Motor Function Classification Skills

Figure 1. Cumulative incidence of cerebral palsy in 24,728 children with and without infant respiratory distress syndrome (IRDS) in Denmark during 1997-2003.



view only

Appendix A. ICD-10 diagnoses codes used in the study retrieved from the Danish National Patient Registry.

	ICD-10 diagnosis code (1994-2009)
Idiopathic respiratory distress syndrome/hyaline membrane disease	DP220+DP22A
Cerebral palsy	DG80, DG81, DG82, DG83
Major malformations <1 year	Q00-99
Complications:	
Bronchopulmonary dysplasia <1 year	DP271
Intraventricular hemorrhage or cerebral leukomalaci <30 days	DB100-DP109
Necrotizing enterocolitis <30 days	DP52 + DP912
Patent ductus arteriosus <30 days	DP77
Other diseases (<4 days after birth date):	
Perinatal breathing disorders and cardiovascular diseases	DP221, DP228, DP229, DP23-DP26, DP28-DP29
Congenital virus infection	DP35
Bacterial infection in newborns	DP36
Infection in the central nervous system (CNS)	DG00-DG09
Pneumonia	DJ12-DJ18

STROBE Statement—We hereby confirm that our manuscript, entitled, “Respiratory distress syndrome in preterm infants and risk of epilepsy” complies with the STROBE guidelines for the reporting of observational studies. Below we have inserted a “Page number” column to indicate where the STROBE Item number has been incorporated into our paper.

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	6-8
		(e) Describe any sensitivity analyses	9

Continued on next page

Results			Page Number
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11
		(b) Indicate number of participants with missing data for each variable of interest	21-22
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-11, 23-24
		(b) Report category boundaries when continuous variables were categorized	10-11, 23-24
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10, 23-24
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-11
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14-15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Respiratory distress syndrome in moderately late and late preterm Infants and risk of cerebral palsy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011643.R1
Article Type:	Research
Date Submitted by the Author:	07-Jun-2016
Complete List of Authors:	Thygesen, Sandra; Aarhus Universitetshospital, Department of Clinical Epidemiology Olsen, Morten; Aarhus University, Department of Clinical Epidemiology Ostergaard, John; Aarhus Universitetshospital, Department of Pediatrics Sørensen, Henrik T.; Aarhus University Hospital, Department of Clinical Epidemiology; Stanford University, Departments of Health Research and Policy (Epidemiology)
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Paediatrics, Neurology, Respiratory medicine
Keywords:	EPIDEMIOLGY, respiratory distress syndrome, cerebral palsy, neurodevelopmental disorder, cohort study, PERINATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **1 Respiratory distress syndrome in moderately late and late preterm infants and risk of**
5
6 **2 cerebral palsy: A population-based cohort study**
7
8

9 Sandra Kruchov Thygesen, Morten Olsen, John R. Østergaard, Henrik Toft Sørensen
10

11
12 **4 Affiliations:**
13

14
15 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
16 Denmark
17 Sandra Kruchov Thygesen
18 MD
19

20 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
21 Denmark
22 Morten Olsen
23 Associate professor
24

25 Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200 Aarhus N,
26 Denmark
27 John R Østergaard
28 Professor
29

30 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
31 Denmark and
32 Departments of Health Research and Policy (Epidemiology), Stanford University, 259 Campus Drive,
33 Stanford, CA 94305, United States
34 Henrik Toft Sørensen
35 Professor
36
37

38 **27 Keywords:** Epidemiology, cohort study, pediatrics, neurology, pulmonary medicine

39
40 **28 Corresponding Author:** Sandra Kruchov Thygesen, st@clin.au.dk, phone: + 45 8716 8063

41
42 **29 Word count:** abstract 300 + article 2,845

43
44 **30 Number of figures:** 1

45
46 **31 Number of tables:** 3

47
48 **32 Number of supplementary file:** 1 (appendix)

49
50 **33 Number of references:** 36
51
52
53
54
55
56
57
58
59
60

1
2
3
4 35 **Abstract**
5
6

7 36 **Objectives:** Infant respiratory distress syndrome (IRDS) is a known risk factor for
8
9 37 intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia. These
10
11 38 lesions are known to increase the risk of cerebral palsy (CP). Thus, we wanted to examine the long-
12
13 39 term risk of CP following IRDS in moderately late and late preterm infants.
14

15
16
17 40 **Design:** Population-based cohort study.
18

19
20 41 **Setting:** All hospitals in Denmark.
21

22
23 42 **Participants:** We used nationwide medical registries to identify a cohort of all moderately and late
24
25 43 preterm infants (defined as birth during 32-36 full gestational weeks) born in Denmark in 1997-
26
27 44 2007 with and without hospital diagnosed IRDS.
28

29
30 45 **Main outcomes measures:** We followed study subjects from birth until first diagnosis of CP,
31
32 46 emigration, death, or end of follow-up in 2014. We computed the cumulative incidence of CP
33
34 47 before age 8 years and used Cox's regression analysis to compute hazard ratios of IRDS, comparing
35
36 48 children with IRDS to those without. Hazard ratios were adjusted for multiple covariates.
37

38
39
40 49 **Results:** We identified 39,420 moderately late and late preterm infants, of whom 2,255 (5.7%) had
41
42 50 IRDS. The cumulative incidence of CP was 1.9% in infants with IRDS and 0.5% in the comparison
43
44 51 cohort. The adjusted hazard ratio of CP was 2.0 [95% confidence interval (CI): 1.4-2.9]. The
45
46 52 adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by ICH/IVH. The
47
48 53 hazard ratio of CP in infants with IRDS that was not accompanied by ICH/IVH was 1.8 (95% CI:
49
50 54 1.3-2.7). After restriction to children without diagnoses of perinatal breathing disorders other than
51
52 55 IRDS, congenital heart disease and viral or bacterial infections occurring within 4 days of birth, the
53
54 56 overall adjusted hazard ratio was 2.1 (95% CI: 1.4-3.1).
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

57 **Conclusion:** The risk of CP was increased in moderately late and late preterm infants with IRDS
58 compared to infants without IRDS born during the same gestational weeks.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-011643 on 11 October 2016. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 59 **Strengths and limitations of this study**

- 5
6 60 • A strength of this study includes the nationwide cohort study design with virtually complete
7
8 61 follow-up, minimizing the risk of selection bias.
- 9
10 62 • To our knowledge, this is the first study to specifically determine the association between
11
12 63 infant respiratory distress syndrome and cerebral palsy utilizing multivariate analysis, and as
13
14 64 such, the validity of the estimates presented is unknown.
- 15
16
17 65 • Even though this study is one of the largest examining a potential association between infant
18
19 66 respiratory distress syndrome and cerebral palsy, it still does not clarify the specific causes
20
21 67 leading to increased risk of cerebral palsy.
22
23
24
25 68

69 Introduction

70 Increasing preterm birth rates over the last few decades have kept the overall incidence of infant
71 respiratory distress syndrome (IRDS) high.¹⁻³ Infant respiratory distress syndrome decreases with
72 increasing gestational age and has a prevalence of about 30% after 32 weeks of gestation.⁴⁻⁶ The
73 condition is caused by lack of surfactant in the lungs, which leads to atelectasis, decreased gas
74 exchange, and hypoxia. Potential complications of IRDS include intracerebral/intraventricular
75 hemorrhage (ICH/IVH) and periventricular leukomalacia (PVL).^{7,8} Studies have reported increased
76 risk of neurodevelopmental impairments, such as neurocognitive and school performance outcomes
77 as well as attention deficit hyperactivity disorder (ADHD) in preterm children with subsequent
78 hypoxic conditions, including IRDS.^{9,10}

79 Cerebral palsy (CP) is the most common cause of severe disabilities in early childhood.¹¹ The core
80 symptom of CP is disorder of movement and/or posture, but is often accompanied by other
81 neurodevelopmental disorders or sensory problems, such as disturbances of sensation, cognition,
82 communication, perception, behavior and/or seizure disorders.¹² The disorder has a multifactorial
83 and poorly understood etiology. The most important risk factor for CP is preterm birth, observed in
84 about 28%–35% of all children with CP.^{13,14} Major lesions that contribute to CP include ICH/IVH
85 and PVL.^{7,15,16}

86 Few data exist on the long term prognosis following IRDS. A few case-control studies have
87 reported indications of an association between IRDS and CP.¹⁷⁻¹⁹ However, these studies are limited
88 by small sample sizes and lack of absolute risk estimates. In the present study, we therefore
89 examined the association between IRDS and CP in a nationwide follow-up study of children born
90 moderately and late preterm.

91

92 **Methods**

93 *Setting and data linkage*

94 We conducted this cohort study using population-based medical databases covering the entire
95 country of Denmark. Linkage between databases was possible through the Civil Registration
96 System (CRS), which has kept electronic records of birth date, date of emigration, and date of death
97 since 1968.²⁰ At birth or upon immigration, all Danish residents are assigned a unique Civil
98 Personal Registration (CPR) number that is used in all public Danish registries. The Danish
99 National Health Service provides free tax-supported health care to the country's 5.6 million
100 citizens.

101 *Study Cohort*

102 Our cohort was identified using the Danish Medical Birth Registry, which contains information on
103 all births in Denmark since 1973. We identified all infants born alive in Denmark from January 1,
104 1997 to December 31, 2007 (approximately 710,000 infants)^{21, 22} and then restricted our cohort to
105 moderately late and late preterm infants (defined as birth between 32 and 36 full weeks). Adequate
106 representation of children both with and without IRDS is available during these gestational weeks.

107 *Infant respiratory distress syndrome*

108 We identified all children diagnosed with IRDS (exposed children) in the Danish National Patient
109 Registry (DNPR). The DNPR contains data on all non-psychiatric hospital admissions in the
110 country since 1977 and on outpatient clinic and emergency room visits since 1995.^{23, 24} Data include
111 dates of admission and discharge, surgical procedure(s) performed, and one primary diagnosis and
112 up to 19 secondary diagnoses coded by the discharging physician according to the *International*

1
2
3
4 113 *Classification of Diseases, Eighth Edition (ICD-8)* until the end of 1993 and the *Tenth Edition*
5
6 114 *(ICD-10)* thereafter.
7
8

9 115 ***Cerebral palsy***

10
11
12 116 Children diagnosed with CP were identified from the Danish National Cerebral Palsy Registry
13
14 117 (DNCPR). Prerequisites for inclusion in this Registry are a prenatal or perinatal aetiology (events
15
16 118 occurring within 28 days of birth.
17

18
19
20 119 All children included in the Registry had their diagnosis externally validated by a child neurologist
21
22 120 at the age of 4-5 years, based on review of clinical findings recorded in the medical files. While the
23
24 121 Registry includes data on prenatally and perinatally acquired cases of CP since 1950, it became
25
26 122 nationwide only in 1995. DNCPR is assumed to cover > 85 % of the children with CP in
27
28 123 Denmark.²⁵ Registry data include subtype and degree of CP,¹¹ predefined ranges of developmental
29
30 124 quotient (DQ: <50, 50-85, >85), motor handicap measured by the Gross Motor Function
31
32 125 Classification System (GMFCS, 0-4) (though only complete until birth year 2003), accompanying
33
34 126 neurological diseases, and orthopedic surgeries. Results of ultrasound and CT scans of the brain and
35
36 127 evaluation of timing of brain damage are available.²⁵ The DQ were mostly based on a clinical
37
38 128 evaluation by a neuropsychiatrist, because the results of the psychological assessments were rarely
39
40 129 available in the medical files. The GMFCS is a tool used to measure gross motor skills in children
41
42 130 with CP. The classification system ranges from level 1 (walking with no support) up to level 5
43
44 131 (immobile/impaired in all areas of motor function).²⁶ We obtained the following study outcomes
45
46 132 from the Registry: overall diagnosis of CP, selected subtypes of CP, (unilateral and bilateral spastic
47
48 133 CP), motor handicap degree (GMFCS levels 1-2, 3, and 4-5), and DQ (<50, 50-85, and >85).
49
50

51
52
53
54 134 ***Covariates***
55
56
57
58
59
60

1
2
3
4 135 We obtained information from the Danish Medical Birth Registry for the entire cohort on
5
6 136 gestational age at birth, 5-minute Apgar score, chorioamnionitis, intrauterine growth restriction,
7
8 137 abruptio placenta, multiplicity, maternal age, and self-reported maternal smoking during
9
10 138 pregnancy.²² In the early years, weeks of gestation was based on weeks since the date of conception
11
12 139 (defined by the first day of the last menstrual period). Later, prenatal ultrasound measurements were also
13
14 140 included as a valid measure for the gestational age. However, in the Danish Medical Birth Registry it is not
15
16 141 possible to distinguish between the methods of measurement used to determine gestational age.²¹ We used
17
18 142 data from the DNPR to ascertain the distribution of complications in children with and without
19
20 143 IRDS, including bronchopulmonary dysplasia, ICH/IVH, necrotizing enterocolitis, and patent
21
22 144 ductus arteriosus (Appendix A). Congenital malformations are associated with increased risk of CP
23
24 145 and also may be associated with IRDS. We therefore ascertained from the DNPR all diagnoses of
25
26 146 congenital malformations detected during the first year of life.

27
28
29
30
31 147 A subgroup of children may have had other conditions within 4 days of birth whose symptoms
32
33 148 potentially overlapped with IRDS, and may potentially lead to misdiagnosis of IRDS. These
34
35 149 diseases include perinatal breathing disorders other than IRDS, congenital heart diseases, and viral
36
37 150 and bacterial infections. We identified these conditions from the DNPR. (Appendix A)

38 39 40 41 151 *Statistical analysis*

42
43
44 152 We followed all children in the study cohort from date of birth until the date of the first diagnosis of
45
46 153 CP, emigration, death, or December 31, 2014, whichever came first. We computed the cumulative
47
48 154 incidence of CP before 8 years of age with death as a competing risk.²⁷ In a sub-analysis, the
49
50 155 commonest sub-types of CP were analyzed as separate outcomes (unilateral and bilateral spastic
51
52 156 CP), as well as motor handicap degree (GMFCS 1-2, 3, and 4-5) (only valid until birth year 2003),
53
54 157 and developmental quotient (<50, 50-85, and >85).

1
2
3
4 158 We used Cox proportional hazard regression to estimate unadjusted and adjusted hazard ratios
5
6 159 (HRs) for CP among children with IRDS compared to children without IRDS. The analyses were
7
8 160 adjusted for gestational age (32, 33, 34, 35, and 36 weeks of gestation), birth year (1997-1999,
9
10 161 2000-2002, 2003-2005, and 2006-2007), gender, multiplicity (singleton/twins), major
11
12 162 malformations, and maternal age (<35 and \geq 35 years of age). The assumptions of proportional
13
14 163 hazards were all verified graphically. We considered a low 5-minute Apgar score as a causal
15
16 164 intermediate step between IRDS and CP, and thus did not include this covariate as a confounder in
17
18 165 the adjusted analyses. However, we did include 5-minute Apgar score in the regression model in a
19
20 166 sub-analysis. Chorioamnionitis, intrauterine growth restriction, and abruptio placenta are important
21
22 167 risk factors of CP and associated with IRDS through low gestational age. Though, they did not
23
24 168 qualify as confounders in the association between IRDS and CP, we did include the three covariates
25
26 169 as confounders in a sub-analysis.

27
28
29
30
31 170 We stratified the analyses on gestational age (birth at 32, 33, 34, and 35-36 full weeks), birth year
32
33 171 (1997-2002, 2003-2007), gender, multiplicity, 5-minute Apgar score (0-6, 7-8, 9-10, missing), and
34
35 172 maternal age (<35 and \geq 35 years of age) and calculated 95% confidence intervals (CIs).

36
37 173 Intracerebral/intraventricular hemorrhage is a known complication of IRDS and an important risk
38
39 174 factor for CP. We therefore repeated the analyses for children with IRDS *and* IVH/ICH within 30
40
41 175 days of birth and children with IRDS *and no* IVH/ICH.

42
43
44
45 176 Perinatal diseases may be misinterpreted as IRDS because of overlapping clinical symptoms or
46
47 177 coexist with IRDS. Such perinatal disorders include perinatal breathing disorders other than IRDS,
48
49 178 congenital heart diseases, and viral and bacterial infections. Thus, in a sensitivity analysis, we
50
51 179 restricted the IRDS cohort to new-borns *with no* other perinatal disorders occurring within 4 days of
52
53 180 birth.

1
2
3
4 181 All analyses were performed using the STATA 13.1 package (StataCorp LP, College Station, TX,
5
6 182 USA). According to Danish legislation, registry-based studies do not need permission from an
7
8 183 ethical board. The study was approved by the Danish Protection Agency (record number: 2014-41-
9
10 184 3183) and did not require informed consent.
11

12 13 185 *Patient involvement*

14
15
16 186 No patients were involved in setting the research question or the outcome measures, nor were they
17
18 187 involved in developing plans for design or implementation of the study. No patients were asked to
19
20 188 advise on interpretation or writing up of results. There are no plans to disseminate the results of the
21
22 189 research to study participants or the relevant patient community.
23
24
25

26 190 27 28 29 191 **Results**

30
31
32 192 From the Danish Medical Birth Registry, we identified 39,420 children born moderately and late
33
34 193 preterm between 1997 and 2007. Of these, 2,255 (5.7%) were diagnosed with IRDS.

35
36 194 Intracerebral/intraventricular haemorrhage (2%) was more common in the IRDS cohort compared
37
38 195 to comparison cohort (0.3%). Having another perinatal disorder occurring within four days of birth,
39
40 196 including perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and
41
42 197 bacterial infection were more prevalent in the children with IRDS (30%) compared to children
43
44 198 without IRDS (18%). (Table 1)
45
46
47

48
49 199 The cumulative incidence of CP before 8 years of age was 1.9 (95% CI: 1.4-2.5) in children with
50
51 200 IRDS and 0.5 (95% CI: 0.4-0.6) in children without IRDS (Figure 1). The overall crude HR for CP
52
53 201 in children with IRDS compared to children without IRDS was 4.0 (95% CI: 2.9-5.6). After
54
55
56
57
58
59
60

1
2
3
4 202 adjusting for gestational age, birth year, gender, multiplicity, major malformations, and maternal
5
6 203 age, the HR was 2.0 (95% CI: 1.4-2.9). (Table 2)
7
8

9 204 When we stratified the analysis by gestational age, we found an increased risk of CP across all
10
11 205 strata in children with IRDS compared to children without IRDS. As well, we found no substantial
12
13 206 variation in the increased risk of CP in children with IRDS across categories of gender, year of
14
15 207 birth, multiplicity, 5-minute Apgar score, and maternal age, although these estimates were less
16
17 208 precise. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by
18
19 209 ICH/IVH and 1.8 (95% CI: 1.3-2.7) in children with IRDS without a diagnosis of ICH/IVH as a
20
21 210 complication.
22
23

24
25 211 Including 5-minute Apgar score as a potential confounder in the regression model did not change
26
27 212 our estimates substantially. The same was evident, when we included chorioamnionitis, intrauterine
28
29 213 growth restriction, and abruptio placenta as potential confounders in the regression analysis (overall
30
31 214 HR of 2.0 (95% CI: 1.4-2.9)). When restricting to children diagnosed with IRDS *and no* other
32
33 215 relevant coexisting diagnoses occurring within 4 days of birth (i.e. perinatal breathing disorders
34
35 216 other than IRDS, congenital heart diseases, and viral and bacterial infections), the overall adjusted
36
37 217 HR was 2.1 (95% CI: 1.4-3.1).
38
39

40
41 218 The most common subtype of CP was unilateral and bilateral spastic CP. (Data not shown) For
42
43 219 children diagnosed with IRDS, we found a HR of 1.5 (95% CI: 0.8-2.9) for unilateral spastic CP
44
45 220 and 2.2 (95% CI: 1.4-3.4) for bilateral spastic CP. The HR was 1.9 (95% CI: 1.1-3.4) for CP with a
46
47 221 normal DQ (above 85), 1.7 (95% CI: 0.9-3.1) for a DQ between 50 and 85, and 2.9 (95% CI: 1.4-
48
49 222 6.1) for a DQ below 50. (Table 3)
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 223 In children with IRDS born during 1997-2003, the HR was 2.2 (95% CI: 1.3-3.9) for a mild degree
5
6 224 of motor handicap (GMFCS 1-2) and 2.5 (95% CI: 1.3-4.7) for a severe degree of motor handicap
7
8 225 (GMFCS 4-5). (Table 3)
9
10

11 226

14 227 **Discussion**

17 228 We found an increased risk of CP associated with IRDS in children born moderately late and late
18
19 229 preterm.

22
23 230 Other studies have shown increased risk of neurodevelopmental impairments, defined by
24
25 231 psychomotor development and school readiness, in preterm children with IRDS.^{9, 10, 28, 29} Studies
26
27 232 have looked at possible causes or predictors of cerebral palsy in different settings and found modest
28
29 233 associations. In an Australian case-control study, Blair et al. reported an odds ratio of CP of 2.3
30
31 234 (95% CI: 1.3-4.3); and in another case-control study from Western Australia, Dite et al. found an
32
33 235 odds ratio of 9.4 (95% CI: 1.8-48) in children diagnosed with IRDS. However; even though they
34
35 236 reported increased risk estimates of CP in children with IRDS, the estimates were based on
36
37 237 univariate analyses in relatively small study populations. Thus, potential confounders were not
38
39 238 taken into consideration and no absolute measures were available.¹⁷⁻¹⁹ In a cohort study, Hirvonen
40
41 239 et al. found a negative association between IRDS and CP in late preterm infants. However,
42
43 240 apparently the multivariate model included intermediate steps between IRDS and CP in terms of
44
45 241 mechanical ventilator treatment and intracranial hemorrhage. Furthermore, the analysis was not
46
47 242 based on time-to-event methods, but based on logistic regression.³⁰ This may have explained the
48
49 243 differences between their results and ours.
50
51
52

53
54 244 Through data linkage performed by the Danish Civil Registration System, this population-based
55
56 245 study had virtually complete follow-up for death, emigration, and hospital admissions, minimizing
57
58
59
60

1
2
3
4 246 the risk of selection bias. Because lack of surfactant cannot be measured directly, the diagnosis of
5
6 247 IRDS is based on the clinical appearance of the infant; thus, it is not possible to make a clear and
7
8 248 consistent diagnostic test. We previously reported a positive predictive value of 89% (95% CI:
9
10 249 75%–96%) for children with IRDS born between 32 and 36 weeks of gestation in the DNPR.³¹ In
11
12 250 this study, IRDS was based exclusively on clinical symptoms, as x-rays were only used infrequently
13
14 251 early in the study period. Additionally, in a sensitivity analysis, we redefined our exposure of
15
16 252 children with IRDS to only those having IRDS with no other perinatal disorders occurring within 4
17
18 253 days of birth. Our estimates were virtually unchanged in this analysis. Because the Cerebral Palsy
19
20 254 Registry is a clinical database based on specific inclusion criteria including thorough medical record
21
22 255 review of all children with CP in Denmark, we expect the positive predictive value of the CP
23
24 256 diagnosis to be close to 100%. A previous validation study of the DNCPR through the DNPR
25
26 257 reported its completeness to be 85%.²⁵ As any misclassification is not likely associated with IRDS,
27
28 258 such non-differential bias would eventually lead to an underestimation of the association between
29
30 259 IRDS and CP.
31
32
33
34
35

36 260 One of the strongest risk factors for development of CP is known to be low gestational age,^{32,33}
37
38 261 which is also the strongest risk factor for IRDS. For this reason, we stratified our analyses on
39
40 262 gestational age to ensure that any increased risk of CP in children with IRDS was not masked by
41
42 263 this association. After taking this precaution, we still found an increased risk of CP among children
43
44 264 born during gestational weeks 32 to 34. Only a few children diagnosed with CP were born during
45
46 265 35 and 36 weeks of gestation, which made calculations of the HR imprecise.
47
48
49

50 266 To study rare disease like CP large study populations are required, especially when the study
51
52 267 sample is restricted to children born at 32-36 gestational weeks. For this reason, we were only able
53
54 268 to present overall estimates in our analyses of selected subtypes of CP, degree of motor handicap,
55
56 269 and DQ. These estimates were all increased throughout all levels of CP severity. Of note, the
57
58
59
60

1
2
3
4 270 prespecified DQ score category, including scores of 50-85, encompassed both children with normal
5
6 271 intelligence as well as delayed children, indicating a diverse group. Thus, not too much emphasis
7
8 272 should be given to this group.
9

10
11 273 Even though this study is among the largest studies examining a potential association between
12
13 274 IRDS and CP by using data from nationwide databases on preterm infants, it still does not clarify
14
15 275 the specific causes of the increased risk of CP. We found a twelve-fold increase of CP in children
16
17 276 with IRDS and ICH/IVH compared to our control population. This suggests an important role of
18
19 277 ICH/IVH in the pathogenesis.^{15, 34, 35} In moderately late and late preterm infants, CNS imaging is
20
21 278 not routinely performed, indicating that some of these children may have an undiagnosed ICH/IVH.
22
23 279 Based on this, the proportion of IRDS patients with ICH/IVH may have been underestimated.
24
25

26
27
28 280 Antenatal corticosteroids decrease the risk of IRDS, as well as ICH/IVH. However, recent studies
29
30 281 have reported adverse neurodevelopment outcomes in children receiving antenatal steroids.³⁶ We
31
32 282 did not have information of treatment with antenatal corticosteroids, which is a limitation of our
33
34 283 study.
35

36
37 284 Infant respiratory distress syndrome potentially could be a surrogate for another unknown medical
38
39 285 condition. However, recognition of an early predictor of increased future CP risk could still be
40
41 286 helpful when planning follow-up and/or intervention strategies in children born preterm.
42
43
44

45 287

48 288 **Conclusion**

49
50
51 289 We found that the risk of CP was twice as high in moderately late and late preterm infants with
52
53 290 IRDS compared to infants without IRDS born during the same gestational weeks. A twelve-fold
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

291 increased risk of CP was found in children with IRDS and ICH/IVH, suggesting an important role
292 of ICH/IVH in the pathogenesis.
293

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-011643 on 11 October 2016. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 294 **Copyright Licence:** The Corresponding Author has the right to grant on behalf of all authors and
5
6 295 does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
7
8 296 perpetuity, in all forms, formats and media (whether known now or created in the future), to i)
9
10 297 publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
11
12 298 other languages, create adaptations, reprints, include within collections and create summaries,
13
14 299 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the
15
16 300 Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic
17
18 301 links from the Contribution to third party material where-ever it may be located; and, vi) licence
19
20 302 any third party to do any or all of the above.
21
22
23
24
25 303

26
27
28 304 **Contributor's Statement:** SKT conceptualized and designed the study, acquired the data, carried
29
30 305 out the analyses, drafted the initial manuscript, reviewed and revised the manuscript, and approved
31
32 306 the final manuscript as submitted. MO, JRO, and HTS conceptualized and designed the study,
33
34 307 supervised the data interpretation, critically reviewed and revised the manuscript for important
35
36 308 intellectual content, and approved the final manuscript as submitted. MO helped to acquire the data
37
38 309 and extract the raw data, critically supervised/reviewed the data analyses and reviewed the data
39
40 310 interpretation, revised the manuscript, and approved the final manuscript as submitted.
41
42
43
44 311

45
46
47 312 **Funding:** This study was supported by grants from the Clinical Epidemiological Research
48
49 313 Foundation ('Klinisk Epidemiologisk Forskningsfond'), Denmark (HTS), and the Program for
50
51 314 Clinical Research Infrastructure (PROCRIN) established by the Lundbeck and the Novo Nordisk
52
53 315 Foundations (HTS). The funding agencies had no role in the design of the study; the collection,
54
55
56
57
58
59
60

1
2
3
4 316 analysis, and interpretation of the data; the writing of the article; or the decision to submit the article
5
6 317 for publication.
7
8

9 318

10
11
12 319 **Competing risk declaration:** All authors have completed the Unified Competing Interest form at
13
14 320 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
15
16 321 declare: no support from any organisation for the submitted work; no financial relationships with
17
18 322 any organisations that might have an interest in the submitted work in the previous three years, and
19
20 323 no other relationships or activities that could appear to have influenced the submitted work
21
22
23

24 324

25
26
27 325 **Ethical approval:** Not needed.
28
29

30 326

31
32
33 327 **Author Statement:** All authors, external and internal, had full access to all of the data (including
34
35 328 statistical reports and tables) in the study and can take responsibility for the integrity of the data and
36
37 329 the accuracy of the data analysis.
38
39

40 330

41
42
43 331 **Transparency declaration:** SKT affirms that the study hypothesis arose before inspection of the
44
45 332 data and that the manuscript is an honest, accurate, and transparent account of the study being
46
47 333 reported; that no important aspects of the study have been omitted; and that any discrepancies from
48
49 334 the study as planned have been explained.
50
51

52 335

53
54
55 336 **Data sharing:** No additional data available.
56
57
58
59
60

337 **References**

- 338 1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of
339 preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic
340 analysis and implications. *Lancet*. 2012;379:2162-72.
- 341 2. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. *Lancet*.
342 2008;371:75-84.
- 343 3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to
344 adulthood. *Lancet*. 2008;371:261-9.
- 345 4. Robertson PA, Sniderman SH, Laros RK, et al. Neonatal morbidity according to gestational age
346 and birth weight from five tertiary care centers in the United States, 1983 through 1986. *Am J*
347 *Obstet Gynecol*. 1992;166:1629,41; discussion 1641-5.
- 348 5. Koivisto M, Marttila R, Kurkinen-Raty M, et al. Changing incidence and outcome of infants with
349 respiratory distress syndrome in the 1990s: a population-based survey. *Acta Paediatr*. 2004;93:177-
350 84.
- 351 6. Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders.
352 A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according
353 to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of
354 Neonatal Pneumology. *Biol Neonate*. 1998;74:7-15.
- 355 7. Kinney HC. The Near-Term (Late Preterm) Human Brain and Risk for Periventricular
356 Leukomalacia: A Review. *Semin Perinatol*. 2006;30:81-8.

- 1
2
3
4 357 8. Sun H, Xu F, Xiong H, et al. Characteristics of respiratory distress syndrome in infants of
5
6 358 different gestational ages. *Lung*. 2013;191:425-33.
7
8
9
10 359 9. McGrath MM, Sullivan MC, Lester BM, et al. Longitudinal Neurologic Follow-Up in Neonatal
11
12 360 Intensive Care Unit Survivors with Various Neonatal Morbidities. *Pediatrics*. 2000;106:1397.
13
14
15 361 10. Getahun D, Rhoads GG, Demissie K, et al. In utero exposure to ischemic-hypoxic conditions
16
17 362 and attention-deficit/hyperactivity disorder. *Pediatrics*. 2013;131:e53-61.
18
19
20
21 363 11. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a
22
23 364 collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe
24
25 365 (SCPE). *Dev Med Child Neurol*. 2000;42:816-24.
26
27
28 366 12. Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral
29
30 367 palsy, April 2005. *Dev Med Child Neurol*. 2005;47:571-6.
31
32
33
34 368 13. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of
35
36 369 genetic variants. *Am J Obstet Gynecol*. 2015;.
37
38
39
40 370 14. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. *Best Pract Res Clin Obstet*
41
42 371 *Gynaecol*. 2004;18:425-36.
43
44
45 372 15. Futagi Y, Toribe Y, Ogawa K, et al. Neurodevelopmental Outcome in Children With
46
47 373 Intraventricular Hemorrhage. *Pediatr Neurol*. 2006;34:219-24.
48
49
50
51 374 16. Blair E, Stanley F. Aetiological pathways to spastic cerebral palsy. *Paediatr Perinat Epidemiol*.
52
53 375 1993;7:302-17.
54
55
56
57
58
59
60

- 1
2
3
4 376 17. Stelmach T, Pisarev H, Talvik T. Ante- and perinatal factors for cerebral palsy: case-control
5
6 377 study in Estonia. *J Child Neurol.* 2005;20:654-60.
7
8
9
10 378 18. Dite GS, Bell R, Reddihough DS, et al. Antenatal and perinatal antecedents of moderate and
11
12 379 severe spastic cerebral palsy. *Aust N Z J Obstet Gynaecol.* 1998;38:377-83.
13
14
15 380 19. Blair E, Stanley F. When can cerebral palsy be prevented? The generation of causal hypotheses
16
17 381 by multivariate analysis of a case-control study. *Paediatr Perinat Epidemiol.* 1993;7:272-301.
18
19
20 382 20. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in
21
22 383 epidemiology. *Eur J Epidemiol.* 2014;29:541-9.
23
24
25
26 384 21. Kristensen J, Langhoff-Roos J, Skovgaard LT, et al. Validation of the Danish Birth
27
28 385 Registration. *J Clin Epidemiol.* 1996;49:893-7.
29
30
31
32 386 22. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull.* 1998;45:320-3.
33
34
35 387 23. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public*
36
37 388 *Health.* 2011;39:30-3.
38
39
40 389 24. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable
41
42 390 source of data for modern health sciences. *Dan Med Bull.* 1999;46:263-8.
43
44
45
46 391 25. Topp M, Langhoff-Roos J, Uldall P. Validation of a cerebral palsy register. *J Clin Epidemiol.*
47
48 392 1997;50:1017-23.
49
50
51
52 393 26. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify
53
54 394 gross motor function in children with cerebral palsy. *Dev Med Child Neurol.* 1997;39:214-23.
55
56
57
58
59
60

- 1
2
3
4 395 27. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of
5
6 396 competing risks: new representations of old estimators. *Stat Med*. 1999;18:695-706.
7
8
9
10 397 28. Piekkala P, Kero P, Sillanpaa M, et al. Growth and development of infants surviving respiratory
11
12 398 distress syndrome: a 2-year follow-up. *Pediatrics*. 1987;79:529-37.
13
14
15 399 29. Patrianakos-Hoobler AI, Msall ME, Marks JD, et al. Risk factors affecting school readiness in
16
17 400 premature infants with respiratory distress syndrome. *Pediatrics*. 2009;124:258-67.
18
19
20
21 401 30. Hirvonen M, Ojala R, Korhonen P, et al. Cerebral palsy among children born moderately and
22
23 402 late preterm. *Pediatrics*. 2014;134:e1584-93.
24
25
26 403 31. Thygesen SK, Olsen M, Christian FC. Positive predictive value of the infant respiratory distress
27
28 404 syndrome diagnosis in the Danish National Patient Registry. *Clin Epidemiol*. 2013;5:295-8.
29
30
31
32 405 32. Sukhov A, Wu Y, Xing G, et al. Risk factors associated with cerebral palsy in preterm infants. *J*
33
34 406 *Matern -Fetal Neonatal Med*. 2012;25:53-7.
35
36
37 407 33. Topp M, Langhoff-Roos J, Uldall P. Preterm birth and cerebral palsy. Predictive value of
38
39 408 pregnancy complications, mode of delivery, and Apgar scores. *Acta Obstet Gynecol Scand*.
40
41 409 1997;76:843-8.
42
43
44
45 410 34. Harcke Jr. HT, Naeye RL, Storch A, et al. Perinatal cerebral intraventricular hemorrhage. *J*
46
47 411 *Pediatr*. 1972;80:37-42.
48
49
50
51 412 35. Berg B. Neurology of the Newborn, 4th Edition, by J.J. Volpe. *Muscle Nerve*. 2001;24:1099-
52
53
54 413 36. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at
55
56 414 Risk for Late Preterm Delivery. *N Engl J Med*. 2016;374:1311-20.
57
58
59
60

1
2
3
4 415 **Figure legend:**

5
6 416 **Figure 1.** Cumulative incidence of cerebral palsy in 24,728 children with and without infant
7 417 respiratory distress syndrome (IRDS) in Denmark during 1997-2003.
8

9
10 418
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

419 **Table 1.** Characteristics of 39,420 infants born during 32–36 weeks of gestation with and without
 420 infant respiratory distress syndrome (IRDS), between January 1, 1997 and December 31, 2007 in
 421 Denmark.

	IRDS, n (%)	No IRDS, n (%)
All	2,255 (100.0)	37,165 (100.0)
Gestational age (week of gestation)		
32	602 (26.7)	2,058 (5.5)
33	545 (24.2)	3,313 (8.9)
34	526 (23.3)	5,652 (15.2)
35	346 (15.3)	9,156 (24.6)
36	236 (10.5)	16,986 (45.7)
Birth year		
1997-1999	534 (23.7)	9,379 (25.2)
2000-2002	602 (26.7)	10,443 (28.1)
2003-2005	696 (30.9)	10,433 (28.1)
2006-2007	423 (18.8)	6,910 (18.6)
Gender		
Female	897 (39.8)	17,184 (46.2)
Male	1,358 (60.2)	19,981 (53.8)
Apgar score at 5 minutes		
Low (0-6)	111 (4.9)	646 (1.7)
Intermediate (7-8)	271 (12.0)	1,824 (4.9)
Normal (9-10)	1,816 (80.5)	33,974 (91.4)
Missing	57 (2.5)	721 (1.9)
Multiplicity		
Singleton	1,644 (72.9)	27,438 (73.8)
Twin	611 (27.1)	9,727 (26.2)
Epilepsy		
	53 (2.4)	590 (1.6)
Major malformation (<1 year)		
	217 (9.6)	2,525 (6.8)
Mother's age at delivery		
<18 years	5 (0.2)	130 (0.4)
18-34 years	1,807 (80.1)	30,131 (81.1)
≥35 years	443 (19.7)	6,903 (18.6)
Missing	0 (0.0)	1 (0.0)
Maternal smoking status		

Non Smoker/former smoker	1,689 (74.9)	26,487 (71.3)
Smoker	403 (17.9)	8,433 (22.7)
Missing	163 (7.2)	2,245 (6.0)

Bronchopulmonary dysplasia (BPD) (<1 year)

Yes	22 (1.0)	16 (0.1)
-----	----------	----------

Intracerebral/intraventricular hemorrhage (ICH/IVH) (<30 days)

Yes	46 (2.0)	121 (0.3)
-----	----------	-----------

Necrotizing enterocolitis (NEC) (<30 days)

Yes	20 (0.9)	59 (0.2)
-----	----------	----------

Patent ductus arteriosus (PDA) (<30 days)

Yes	77 (3.4)	239 (0.6)
-----	----------	-----------

Other diseases*

Yes	682 (30.2)	6,641 (17.9)
-----	------------	--------------

422 *Other diseases whose symptoms may overlap with those of IRDS, occurring within 4 days of birth
423 (perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and bacterial infections).

424

425

Table 2. Hazard ratios of cerebral palsy (CP) by age 8 among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark. (N=39,410)

	Number of children with CP		8-year cumulative incidence, % (95% confidence interval (CI))		Crude hazard ratio (95% CI)	Adjusted hazard ratio* (95% CI)
	Children with IRDS	Children without IRDS	Children with IRDS	Children without IRDS		
Overall	42	178	1.9 (1.4-2.5)	0.5 (0.4-0.6)	4.0 (2.9-5.6)	2.0 (1.4-2.9)
Gestational age						
32 weeks of gestation	21	31	3.5 (2.2-5.2)	1.5 (1.1-2.1)	2.3 (1.3-4.0)	2.4 (1.4-4.2)
33 weeks of gestation	11	44	2.0 (1.1-3.5)	1.3 (1.0-1.7)	1.6 (0.8-3.1)	1.6 (0.8-3.1)
34 weeks of gestation	7	30	1.4 (0.6-2.7)	0.5 (0.4-0.8)	2.5 (1.1-5.8)	2.5 (1.1-5.8)
[35-36] weeks of gestation	3	73	0.5 (0.1-1.4)	0.3 (0.2-0.4)	1.9 (0.6-6.1)	1.7 (0.5-5.5)
Calendar year						
[1997-2002]	28	105	2.5 (1.7-3.5)	0.5 (0.4-0.6)	4.8 (3.2-7.3)	2.4 (1.5-3.7)
[2003-2007]	14	73	1.3 (0.7-2.1)	0.4 (0.3-0.5)	3.1 (1.7-5.4)	1.4 (0.8-2.6)
Gender						
Female	14	76	1.6 (0.9-2.6)	0.4 (0.4-0.6)	3.6 (2.1-6.4)	1.7 (0.9-3.1)
Male	28	102	2.1 (1.4-3.0)	0.5 (0.4-0.6)	4.2 (2.7-6.3)	2.2 (1.4-3.4)
Apgar score at 5 minutes						
Low (0-6)	4	10	3.7 (1.2-8.5)	1.6 (0.8-2.8)	2.1 (0.7-6.8)	2.2 (0.7-7.7)
Intermediate (7-8)	7	31	2.6 (1.2-5.0)	1.7 (1.2-2.4)	1.6 (0.7-3.5)	1.2 (0.5-2.8)
Normal (9-10)	28	131	1.6 (1.1-2.2)	0.4 (0.3-0.5)	4.1 (2.7-6.2)	1.9 (1.2-2.9)
Missing	3	6	5.3 (1.4-13)	0.8 (0.4-1.8)	6.6 (1.6-26)	6.0 (1.0-35)
Multiplicity						
Singleton	29	129	1.8 (1.2-2.5)	0.5 (0.4-0.6)	3.9 (2.6-5.8)	2.0 (1.3-3.1)
Twin	13	49	2.1 (1.2-3.5)	0.5 (0.4-0.7)	4.3 (2.3-7.9)	1.9 (1.0-3.6)

Maternal age						
Younger than 35 years of age	31	138	1.7 (1.2-2.4)	0.5 (0.4-0.5)	3.9 (2.6-5.7)	1.9 (1.3-2.9)
35 years of age or older	11	40	2.5 (1.3-4.3)	0.6 (0.4-0.8)	4.4 (2.3-8.6)	2.3 (1.1-4.8)

*Adjusted for sex, gestational age, infant's birth year, multiplicity, major malformations, and maternal age.

For peer review only

Table 3. Hazard ratios of cerebral palsy (CP) among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark.

	Number of children with CP		Crude hazard ratio (95% CI)*	Adjusted hazard ratio (95% CI)
	Children with IRDS	Children without IRDS		
Selected sub-types[†]				
Unilateral spastic CP	12	74	2.7 (1.5-5.0)	1.5 (0.8-2.9)
Bilateral spastic CP	26	87	5.1 (3.3-7.9)	2.2 (1.4-3.4)
Motor Handicap [1997-2003][‡]				
GMFCS [§] 1-2	16	71	4.0 (2.3-6.8)	2.2 (1.3-3.9)
GMFCS 3	1	4	4.4 (0.5-39)	2.2 (0.2-21)
GMFCS 4-5	4	70	6.1 (3.3-11)	2.5 (1.3-4.7)
Developmental Quotient (DQ)[¶]				
DQ <50	11	33	5.6 (2.8-11)	2.9 (1.4-6.1)
DQ 50-85	14	60	3.9 (2.2-7.0)	1.7 (0.9-3.1)
DQ >85	17	80	3.6 (2.1-6.1)	1.9 (1.1-3.4)

*Confidence interval

[†]Only selected sub-types are included

[‡]The covariate is only valid in 1997-2003 and had missing information for 2 CP cases

[§]Gross Motor Function Classification Skills

[¶]The DQ covariate had missing data for 5 CP cases. Of note, we did complete case analysis




Figure 1. Cumulative incidence of cerebral palsy in 24,728 children with and without infant respiratory distress syndrome (IRDS) in Denmark during 1997-2003.

(Figure A)

55x40mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Appendix A.** ICD-10 diagnoses codes used in the study retrieved from the Danish National Patient Registry.

	ICD-10 diagnosis code (1994-2009)
Idiopathic respiratory distress syndrome/hyaline membrane disease	DP220+DP22A
Cerebral palsy	DG80, DG81, DG82, DG83
Major malformations <1 year	Q00-99
Complications:	
Bronchopulmonary dysplasia <1 year	DP271
Intraventricular hemorrhage or cerebral leukomalaci <30 days	DB100-DP109
Necrotizing enterocolitis <30 days	DP52 + DP912
Patent ductus arteriosus <30 days	DP77
Other diseases (<4 days after birth date):	
Perinatal breathing disorders and cardiovascular diseases	DP221, DP228, DP229, DP23-DP26, DP28-DP29
Congenital virus infection	DP35
Bacterial infection in newborns	DP36
Infection in the central nervous system (CNS)	DG00-DG09
Pneumonia	DJ12-DJ18

STROBE Statement—We hereby confirm that our manuscript, entitled, “Respiratory distress syndrome in preterm infants and risk of cerebral palsy: A population-based cohort study” complies with the STROBE guidelines for the reporting of observational studies. Below we have inserted a “Page number” column to indicate where the STROBE Item number has been incorporated into our paper.

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	6-8
		(e) Describe any sensitivity analyses	9

Continued on next page

Results			Page Number
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11
		(b) Indicate number of participants with missing data for each variable of interest	24-25
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-11, 26-28
		(b) Report category boundaries when continuous variables were categorized	10-11, 24-25
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10, 26-28
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12, 28
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16-17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Respiratory distress syndrome in moderately late and late preterm Infants and risk of cerebral palsy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011643.R2
Article Type:	Research
Date Submitted by the Author:	18-Aug-2016
Complete List of Authors:	Thygesen, Sandra; Aarhus Universitetshospital, Department of Clinical Epidemiology Olsen, Morten; Aarhus University, Department of Clinical Epidemiology Ostergaard, John; Aarhus Universitetshospital, Department of Pediatrics Sørensen, Henrik T.; Aarhus University Hospital, Department of Clinical Epidemiology; Stanford University, Departments of Health Research and Policy (Epidemiology)
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Paediatrics, Neurology, Respiratory medicine
Keywords:	EPIDEMIOLGY, respiratory distress syndrome, cerebral palsy, neurodevelopmental disorder, cohort study, PERINATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Respiratory distress syndrome in moderately late and late preterm infants and risk of**
5
6 **cerebral palsy: A population-based cohort study**
7
8

9 Sandra Kruchov Thygesen, Morten Olsen, John R. Østergaard, Henrik Toft Sørensen
10

11
12 **Affiliations:**
13

14
15 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
16 Denmark
17 Sandra Kruchov Thygesen
18 MD
19

20
21 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
22 Denmark
23 Morten Olsen
24 Associate professor

25
26 Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200 Aarhus N,
27 Denmark
28 John R Østergaard
29 Professor

30
31 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
32 Denmark and
33 Departments of Health Research and Policy (Epidemiology), Stanford University, 259 Campus Drive,
34 Stanford, CA 94305, United States
35 Henrik Toft Sørensen
36 Professor

37
38 **Keywords:** Epidemiology, cohort study, pediatrics, neurology, pulmonary medicine

39
40 **Corresponding Author:** Sandra Kruchov Thygesen, st@clin.au.dk, phone: + 45 8716 8063

41
42 **Word count:** abstract 300 + article 2,845

43
44 **Number of figures:** 1

45
46 **Number of tables:** 3

47
48 **Number of supplementary file:** 1 (appendix)

49
50 **Number of references:** 36
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Infant respiratory distress syndrome (IRDS) is a known risk factor for intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia. These lesions are known to increase the risk of cerebral palsy (CP). Thus, we wanted to examine the long-term risk of CP following IRDS in moderately late and late preterm infants.

Design: Population-based cohort study.

Setting: All hospitals in Denmark.

Participants: We used nationwide medical registries to identify a cohort of all moderately and late preterm infants (defined as birth during 32-36 full gestational weeks) born in Denmark in 1997-2007 with and without hospital diagnosed IRDS.

Main outcomes measures: We followed study subjects from birth until first diagnosis of CP, emigration, death, or end of follow-up in 2014. We computed the cumulative incidence of CP before age 8 years and used Cox's regression analysis to compute hazard ratios of IRDS, comparing children with IRDS to those without. Hazard ratios were adjusted for multiple covariates.

Results: We identified 39,420 moderately late and late preterm infants, of whom 2,255 (5.7%) had IRDS. The cumulative incidence of CP was 1.9% in infants with IRDS and 0.5% in the comparison cohort. The adjusted hazard ratio of CP was 2.0 [95% confidence interval (CI): 1.4-2.9]. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by a diagnosis of ICH/IVH. After restriction to children without diagnoses of perinatal breathing disorders other than IRDS, congenital heart disease and viral or bacterial infections occurring within 4 days of birth, the overall adjusted hazard ratio was 2.1 (95% CI: 1.4-3.1).

1
2
3
4 **Conclusion:** The risk of CP was increased in moderately late and late preterm infants with IRDS
5
6 compared to infants without IRDS born during the same gestational weeks.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- A strength of this study includes the nationwide cohort study design with virtually complete follow-up, minimizing the risk of selection bias.
- To our knowledge, this is the first study to specifically determine the association between infant respiratory distress syndrome and cerebral palsy utilizing multivariate analysis, and as such, the validity of the estimates presented is unknown.
- Even though this study is one of the largest examining a potential association between infant respiratory distress syndrome and cerebral palsy, it still does not clarify the specific causes leading to increased risk of cerebral palsy.

Introduction

Increasing preterm birth rates over the last few decades have kept the overall incidence of infant respiratory distress syndrome (IRDS) high.¹⁻³ Infant respiratory distress syndrome decreases with increasing gestational age and has a prevalence of about 30% after 32 weeks of gestation.⁴⁻⁶ The condition is caused by lack of surfactant in the lungs, which leads to atelectasis, decreased gas exchange, and hypoxia. Potential complications of IRDS include intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia (PVL).^{7,8} Studies have reported increased risk of neurodevelopmental impairments, such as neurocognitive and school performance outcomes as well as attention deficit hyperactivity disorder (ADHD) in preterm children with subsequent hypoxic conditions, including IRDS.^{9,10}

Cerebral palsy (CP) is the most common cause of severe disabilities in early childhood.¹¹ The core symptom of CP is disorder of movement and/or posture, but is often accompanied by other neurodevelopmental disorders or sensory problems, such as disturbances of sensation, cognition, communication, perception, behavior and/or seizure disorders.¹² The disorder has a multifactorial and poorly understood etiology. The most important risk factor for CP is preterm birth, observed in about 28%–35% of all children with CP.^{13,14} Major lesions that contribute to CP include ICH/IVH and PVL.^{7,15,16}

Few data exist on the long term prognosis following IRDS. A few case-control studies have reported indications of an association between IRDS and CP.¹⁷⁻¹⁹ However, these studies are limited by small sample sizes and lack of absolute risk estimates. In the present study, we therefore examined the association between IRDS and CP in a nationwide follow-up study of children born moderately and late preterm.

Methods

Setting and data linkage

We conducted this cohort study using population-based medical databases covering the entire country of Denmark. Linkage between databases was possible through the Civil Registration System (CRS), which has kept electronic records of birth date, date of emigration, and date of death since 1968.²⁰ At birth or upon immigration, all Danish residents are assigned a unique Civil Personal Registration (CPR) number that is used in all public Danish registries. The Danish National Health Service provides free tax-supported health care to the country's 5.6 million citizens.

Study Cohort

Our cohort was identified using the Danish Medical Birth Registry, which contains information on all births in Denmark since 1973. We identified all infants born alive in Denmark from January 1, 1997 to December 31, 2007 (approximately 710,000 infants)^{21, 22} and then restricted our cohort to moderately late and late preterm infants (defined as birth between 32 and 36 full weeks). Adequate representation of children both with and without IRDS is available during these gestational weeks.

Infant respiratory distress syndrome

We identified all children diagnosed with IRDS (exposed children) in the Danish National Patient Registry (DNPR). The DNPR contains data on all non-psychiatric hospital admissions in the country since 1977 and on outpatient clinic and emergency room visits since 1995.^{23, 24} Data include dates of admission and discharge, surgical procedure(s) performed, and one primary diagnosis and up to 19 secondary diagnoses coded by the discharging physician according to the *International*

1
2
3
4 *Classification of Diseases, Eighth Edition (ICD-8)* until the end of 1993 and the *Tenth Edition*
5
6 (ICD-10) thereafter.
7
8

9 ***Cerebral palsy***

10
11
12 Children diagnosed with CP were identified from the Danish National Cerebral Palsy Registry
13 (DNCPR). Prerequisites for inclusion in this Registry are a prenatal or perinatal aetiology (events
14 occurring within 28 days of birth.
15
16

17
18
19 All children included in the Registry had their diagnosis externally validated by a child neurologist
20 at the age of 4-5 years, based on review of clinical findings recorded in the medical files. While the
21 Registry includes data on prenatally and perinatally acquired cases of CP since 1950, it became
22 nationwide only in 1995. DNCPR is assumed to cover > 85 % of the children with CP in
23
24 Denmark.²⁵ Registry data include subtype and degree of CP,¹¹ predefined ranges of developmental
25 quotient (DQ: <50, 50-85, >85), motor handicap measured by the Gross Motor Function
26 Classification System (GMFCS, 0-4) (though only complete until birth year 2003), accompanying
27 neurological diseases, and orthopedic surgeries. Results of ultrasound and CT scans of the brain and
28 evaluation of timing of brain damage are available.²⁵ The DQ were mostly based on a clinical
29 evaluation by a neuropsychiatrist, because the results of the psychological assessments were rarely
30 available in the medical files. The GMFCS is a tool used to measure gross motor skills in children
31 with CP. The classification system ranges from level 1 (walking with no support) up to level 5
32 (immobile/impaired in all areas of motor function).²⁶ We obtained the following study outcomes
33 from the Registry: overall diagnosis of CP, selected subtypes of CP, (unilateral and bilateral spastic
34 CP), motor handicap degree (GMFCS levels 1-2, 3, and 4-5), and DQ (<50, 50-85, and >85).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 ***Covariates***

54
55
56
57
58
59
60

1
2
3
4 We obtained information from the Danish Medical Birth Registry for the entire cohort on
5 gestational age at birth, 5-minute Apgar score, chorioamnionitis, intrauterine growth restriction,
6 abruptio placenta, multiplicity, maternal age, and self-reported maternal smoking during
7 pregnancy.²² Of note, information on administration of antenatal corticosteroids was not available.
8
9 In the early years, weeks of gestation was based on the first day of the last menstrual period. Later,
10 prenatal ultrasound measurements were also included as a valid measure for the gestational age.
11
12 However, in the Danish Medical Birth Registry it is not possible to distinguish between the methods
13 of measurement used to determine gestational age.²¹ We used data from the DNPR to ascertain the
14 distribution of complications in children with and without IRDS, including bronchopulmonary
15 dysplasia, ICH/IVH, necrotizing enterocolitis, and patent ductus arteriosus (Appendix A).
16
17 Congenital malformations are associated with increased risk of CP and also may be associated with
18 IRDS. We therefore ascertained from the DNPR all diagnoses of congenital malformations detected
19 during the first year of life.
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34 A subgroup of children may have had other conditions within 4 days of birth whose symptoms
35 potentially overlapped with IRDS, and may potentially lead to misdiagnosis of IRDS. These
36 diseases include perinatal breathing disorders other than IRDS, congenital heart diseases, and viral
37 and bacterial infections. We identified these conditions from the DNPR. (Appendix A)
38
39
40
41
42

43 *Statistical analysis*

44
45
46 We followed all children in the study cohort from date of birth until the date of the first diagnosis of
47 CP, emigration, death, or December 31, 2014, whichever came first. We computed the cumulative
48 incidence of CP before 8 years of age with death as a competing risk.²⁷ In a sub-analysis, the
49 commonest sub-types of CP were analyzed as separate outcomes (unilateral and bilateral spastic
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 CP), as well as motor handicap degree (GMFCS 1-2, 3, and 4-5) (only valid until birth year 2003),
5
6 and developmental quotient (<50,50-85, and >85).
7
8

9
10 We used Cox proportional hazard regression to estimate unadjusted and adjusted hazard ratios
11 (HRs) for CP among children with IRDS compared to children without IRDS. The analyses were
12 adjusted for gestational age (32, 33, 34, 35, and 36 weeks of gestation), birth year (1997-1999,
13 2000-2002, 2003-2005, and 2006-2007), gender, multiplicity (singleton/twins), major
14 malformations, and maternal age (<35 and \geq 35 years of age). The assumptions of proportional
15 hazards were all verified graphically. We considered a low 5-minute Apgar score as a causal
16 intermediate step between IRDS and CP, and thus did not include this covariate as a confounder in
17 the adjusted analyses. However, we did include 5-minute Apgar score in the regression model in a
18 sub-analysis. Chorioamnionitis, intrauterine growth restriction, and abruptio placenta are important
19 independent risk factors of CP. Moreover, these conditions are associated with IRDS, not
20 independently, but through low gestational age. Though, they did not qualify as confounders in the
21 association between IRDS and CP, we did include the three covariates as confounders in a sub-
22 analysis.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 We stratified the analyses on gestational age (birth at 32, 33, 34, and 35-36 full weeks), birth year
40 (1997-2002, 2003-2007), gender, multiplicity, 5-minute Apgar score (0-6, 7-8, 9-10, missing), and
41 maternal age (<35 and \geq 35 years of age) and calculated 95% confidence intervals (CIs).
42
43
44

45 Intracerebral/intraventricular hemorrhage is a known complication of IRDS and an important risk
46 factor for CP. We therefore repeated the analyses for children with IRDS *and* IVH/ICH within 30
47 days of birth and children with IRDS *and no* IVH/ICH. Of note, ICH/IVH is not performed as a
48 routine in moderately late and late preterm infants, so this proportion of infants only include infants
49 who presented with a clinical presentation and for that reason had indication for at head ultrasound.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Perinatal diseases may be misinterpreted as IRDS because of overlapping clinical symptoms or
5
6 coexist with IRDS. Such perinatal disorders include perinatal breathing disorders other than IRDS,
7
8 congenital heart diseases, and viral and bacterial infections. Thus, in a sensitivity analysis, we
9
10 restricted the IRDS cohort to new-borns *with no* other perinatal disorders occurring within 4 days of
11
12 birth.

13
14
15 All analyses were performed using the STATA 13.1 package (StataCorp LP, College Station, TX,
16
17 USA). According to Danish legislation, registry-based studies do not need permission from an
18
19 ethical board. The study was approved by the Danish Protection Agency (record number: 2014-41-
20
21 3183) and did not require informed consent.

22 23 24 25 ***Patient involvement***

26
27
28 No patients were involved in setting the research question or the outcome measures, nor were they
29
30 involved in developing plans for design or implementation of the study. No patients were asked to
31
32 advise on interpretation or writing up of results. There are no plans to disseminate the results of the
33
34 research to study participants or the relevant patient community.

35 36 37 38 39 40 41 **Results**

42
43
44 From the Danish Medical Birth Registry, we identified 39,420 children born moderately and late
45
46 preterm between 1997 and 2007. Of these, 2,255 (5.7%) were diagnosed with IRDS. Having
47
48 another perinatal disorder occurring within four days of birth, including perinatal breathing
49
50 disorders other than IRDS, congenital heart diseases, and viral and bacterial infection were more
51
52 prevalent in the children with IRDS (30%) compared to children without IRDS (18%). (Table 1)

1
2
3
4 The cumulative incidence of CP before 8 years of age was 1.9 (95% CI: 1.4-2.5) in children with
5 IRDS and 0.5 (95% CI: 0.4-0.6) in children without IRDS (Figure 1). The overall crude HR for CP
6 in children with IRDS compared to children without IRDS was 4.0 (95% CI: 2.9-5.6). After
7
8 adjusting for gestational age, birth year, gender, multiplicity, major malformations, and maternal
9
10 age, the HR was 2.0 (95% CI: 1.4-2.9). (Table 2)

11
12
13
14
15
16 When we stratified the analysis by gestational age, we found an increased risk of CP across all
17 strata in children with IRDS compared to children without IRDS. As well, we found no substantial
18 variation in the increased risk of CP in children with IRDS across categories of gender, year of
19 birth, multiplicity, 5-minute Apgar score, and maternal age, although these estimates were less
20 precise. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by a
21 discharge diagnosis of ICH/IVH.
22
23
24
25
26
27
28
29

30 Including 5-minute Apgar score as a potential confounder in the regression model did not change
31 our estimates substantially. The same was evident, when we included chorioamnionitis, intrauterine
32 growth restriction, and abruptio placenta as potential confounders in the regression analysis (overall
33 HR of 2.0 (95% CI: 1.4-2.9)). When restricting to children diagnosed with IRDS *and no* other
34 relevant coexisting diagnoses occurring within 4 days of birth (i.e. perinatal breathing disorders
35 other than IRDS, congenital heart diseases, and viral and bacterial infections), the overall adjusted
36 HR was 2.1 (95% CI: 1.4-3.1).
37
38
39
40
41
42
43
44
45

46 The most common subtype of CP was unilateral and bilateral spastic CP. (Data not shown) For
47 children diagnosed with IRDS, we found a HR of 1.5 (95% CI: 0.8-2.9) for unilateral spastic CP
48 and 2.2 (95% CI: 1.4-3.4) for bilateral spastic CP. The HR was 1.9 (95% CI: 1.1-3.4) for CP with a
49 normal DQ (above 85), 1.7 (95% CI: 0.9-3.1) for a DQ between 50 and 85, and 2.9 (95% CI: 1.4-
50 6.1) for a DQ below 50. (Table 3)
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In children with IRDS born during 1997-2003, the HR was 2.2 (95% CI: 1.3-3.9) for a mild degree
5
6 of motor handicap (GMFCS 1-2) and 2.5 (95% CI: 1.3-4.7) for a severe degree of motor handicap
7
8 (GMFCS 4-5). (Table 3)
9

14 Discussion

15
16
17 We found an increased risk of CP associated with IRDS in children born moderately late and late
18
19 preterm.
20

21
22
23 Other studies have shown increased risk of neurodevelopmental impairments, defined by
24
25 psychomotor development and school readiness, in preterm children with IRDS.^{9, 10, 28, 29} Studies
26
27 have looked at possible causes or predictors of cerebral palsy in different settings and found modest
28
29 associations. In an Australian case-control study, Blair et al. reported an odds ratio of CP of 2.3
30
31 (95% CI: 1.3-4.3); and in another case-control study from Western Australia, Dite et al. found an
32
33 odds ratio of 9.4 (95% CI: 1.8-48) in children diagnosed with IRDS. However; even though they
34
35 reported increased risk estimates of CP in children with IRDS, the estimates were based on
36
37 univariate analyses in relatively small study populations. Thus, potential confounders were not
38
39 taken into consideration and no absolute measures were available.¹⁷⁻¹⁹ In a cohort study, Hirvonen
40
41 et al. found a negative association between IRDS and CP in late preterm infants. However,
42
43 apparently the multivariate model included intermediate steps between IRDS and CP in terms of
44
45 mechanical ventilator treatment and intracranial hemorrhage. Furthermore, the analysis was not
46
47 based on time-to-event methods, but based on logistic regression.³⁰ This may have explained the
48
49 differences between their results and ours.
50
51
52

53
54
55 Through data linkage performed by the Danish Civil Registration System, this population-based
56
57 study had virtually complete follow-up for death, emigration, and hospital admissions, minimizing
58
59
60

1
2
3
4 the risk of selection bias. Because lack of surfactant cannot be measured directly, the diagnosis of
5
6 IRDS is based on the clinical appearance of the infant; thus, it is not possible to make a clear and
7
8 consistent diagnostic test. We previously reported a positive predictive value of 89% (95% CI:
9
10 75%–96%) for children with IRDS born between 32 and 36 weeks of gestation in the DNPR.³¹ In
11
12 this study, IRDS was based exclusively on clinical symptoms, as x-rays were only used infrequently
13
14 early in the study period. Additionally, in a sensitivity analysis, we redefined our exposure of
15
16 children with IRDS to only those having IRDS with no other perinatal disorders occurring within 4
17
18 days of birth. Our estimates were virtually unchanged in this analysis. Because the Cerebral Palsy
19
20 Registry is a clinical database based on specific inclusion criteria including thorough medical record
21
22 review of all children with CP in Denmark, we expect the positive predictive value of the CP
23
24 diagnosis to be close to 100%. A previous validation study of the DNCPR through the DNPR
25
26 reported its completeness to be 85%.²⁵ As any misclassification is not likely associated with IRDS,
27
28 such non-differential bias would eventually lead to an underestimation of the association between
29
30 IRDS and CP.
31
32
33
34
35

36 One of the strongest risk factors for development of CP is known to be low gestational age,^{32,33}
37
38 which is also the strongest risk factor for IRDS. For this reason, we stratified our analyses on
39
40 gestational age to ensure that any increased risk of CP in children with IRDS was not masked by
41
42 this association. After taking this precaution, we still found an increased risk of CP among children
43
44 born during gestational weeks 32 to 34. Only a few children diagnosed with CP were born during
45
46 35 and 36 weeks of gestation, which made calculations of the HR imprecise.
47
48
49

50 To study rare disease like CP large study populations are required, especially when the study
51
52 sample is restricted to children born at 32-36 gestational weeks. For this reason, we were only able
53
54 to present overall estimates in our analyses of selected subtypes of CP, degree of motor handicap,
55
56 and DQ. These estimates were all increased throughout all levels of CP severity. Of note, the
57
58
59
60

1
2
3
4 prespecified DQ score category, including scores of 50-85, encompassed both children with normal
5
6 intelligence as well as delayed children, indicating a diverse group. Thus, not too much emphasis
7
8 should be given to this group.
9

10
11 Even though this study is among the largest studies examining a potential association between
12
13 IRDS and CP by using data from nationwide databases on preterm infants, it still does not clarify
14
15 the specific causes of the increased risk of CP. We found a twelve-fold increase of CP in children
16
17 with IRDS and a diagnosis of ICH/IVH compared to our control population. This may suggest an
18
19 important role of ICH/IVH in the pathogenesis, though this is only speculations.^{15, 34, 35} In
20
21 moderately late and late preterm infants, CNS imaging is not routinely performed, indicating that
22
23 some of these children may have an undiagnosed ICH/IVH. Based on this, the proportion of IRDS
24
25 patients with ICH/IVH may have been underestimated.
26
27

28
29 Antenatal corticosteroids decrease the risk of IRDS, as well as ICH/IVH. However, recent studies
30
31 have reported adverse neurodevelopment outcomes in children receiving antenatal steroids.³⁶ We
32
33 did not have information of treatment with antenatal corticosteroids, which is a limitation of our
34
35 study.
36
37

38
39 Infant respiratory distress syndrome potentially could be a surrogate for another unknown medical
40
41 condition. However, recognition of an early predictor of increased future CP risk could still be
42
43 helpful when planning follow-up and/or intervention strategies in children born preterm.
44
45
46
47
48
49

50 **Conclusion**

51
52
53 We found that the risk of CP was twice as high in moderately late and late preterm infants with
54
55 IRDS compared to infants without IRDS born during the same gestational weeks.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Copyright Licence:** The Corresponding Author has the right to grant on behalf of all authors and
5 does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

perpetuity, in all forms, formats and media (whether known now or created in the future), to i)
publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
other languages, create adaptations, reprints, include within collections and create summaries,
extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the
Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic
links from the Contribution to third party material where-ever it may be located; and, vi) licence
any third party to do any or all of the above.

Contributor's Statement: SKT conceptualized and designed the study, acquired the data, carried
out the analyses, drafted the initial manuscript, reviewed and revised the manuscript, and approved
the final manuscript as submitted. MO, JRO, and HTS conceptualized and designed the study,
supervised the data interpretation, critically reviewed and revised the manuscript for important
intellectual content, and approved the final manuscript as submitted. MO helped to acquire the data
and extract the raw data, critically supervised/reviewed the data analyses and reviewed the data
interpretation, revised the manuscript, and approved the final manuscript as submitted.

Funding: This study was supported by grants from the Clinical Epidemiological Research
Foundation ('Klinisk Epidemiologisk Forskningsfond'), Denmark (HTS), and the Program for
Clinical Research Infrastructure (PROCRIN) established by the Lundbeck and the Novo Nordisk
Foundations (HTS). The funding agencies had no role in the design of the study; the collection,

1
2
3
4 analysis, and interpretation of the data; the writing of the article; or the decision to submit the article
5
6 for publication.
7
8
9

10
11
12 **Competing risk declaration:** All authors have completed the Unified Competing Interest form at
13 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
14
15 declare: no support from any organisation for the submitted work; no financial relationships with
16
17 any organisations that might have an interest in the submitted work in the previous three years, and
18
19 no other relationships or activities that could appear to have influenced the submitted work
20
21
22
23
24
25
26

27 **Ethical approval:** Not needed.
28
29
30
31
32

33 **Author Statement:** All authors, external and internal, had full access to all of the data (including
34
35 statistical reports and tables) in the study and can take responsibility for the integrity of the data and
36
37 the accuracy of the data analysis.
38
39
40
41
42

43 **Transparency declaration:** SKT affirms that the study hypothesis arose before inspection of the
44
45 data and that the manuscript is an honest, accurate, and transparent account of the study being
46
47 reported; that no important aspects of the study have been omitted; and that any discrepancies from
48
49 the study as planned have been explained.
50
51
52
53
54
55

56 **Data sharing:** No additional data available.
57
58
59
60

References

1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet*. 2012;379:2162-72.
2. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. *Lancet*. 2008;371:75-84.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet*. 2008;371:261-9.
4. Robertson PA, Sniderman SH, Laros RK, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. *Am J Obstet Gynecol*. 1992;166:1629,41; discussion 1641-5.
5. Koivisto M, Marttila R, Kurkinen-Raty M, et al. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990s: a population-based survey. *Acta Paediatr*. 2004;93:177-84.
6. Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. *Biol Neonate*. 1998;74:7-15.
7. Kinney HC. The Near-Term (Late Preterm) Human Brain and Risk for Periventricular Leukomalacia: A Review. *Semin Perinatol*. 2006;30:81-8.

- 1
2
3
4 8. Sun H, Xu F, Xiong H, et al. Characteristics of respiratory distress syndrome in infants of
5
6 different gestational ages. *Lung*. 2013;191:425-33.
7
8
- 9
10 9. McGrath MM, Sullivan MC, Lester BM, et al. Longitudinal Neurologic Follow-Up in Neonatal
11
12 Intensive Care Unit Survivors with Various Neonatal Morbidities. *Pediatrics*. 2000;106:1397.
13
14
- 15 10. Getahun D, Rhoads GG, Demissie K, et al. In utero exposure to ischemic-hypoxic conditions
16
17 and attention-deficit/hyperactivity disorder. *Pediatrics*. 2013;131:e53-61.
18
19
- 20 11. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a
21
22 collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe
23
24 (SCPE). *Dev Med Child Neurol*. 2000;42:816-24.
25
26
- 27 12. Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral
28
29 palsy, April 2005. *Dev Med Child Neurol*. 2005;47:571-6.
30
31
- 32 13. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of
33
34 genetic variants. *Am J Obstet Gynecol*. 2015;.
35
36
- 37 14. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. *Best Pract Res Clin Obstet*
38
39 *Gynaecol*. 2004;18:425-36.
40
41
- 42 15. Futagi Y, Toribe Y, Ogawa K, et al. Neurodevelopmental Outcome in Children With
43
44 Intraventricular Hemorrhage. *Pediatr Neurol*. 2006;34:219-24.
45
46
- 47 16. Blair E, Stanley F. Aetiological pathways to spastic cerebral palsy. *Paediatr Perinat Epidemiol*.
48
49 1993;7:302-17.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Stelmach T, Pisarev H, Talvik T. Ante- and perinatal factors for cerebral palsy: case-control
5 study in Estonia. *J Child Neurol.* 2005;20:654-60.
6
7
8
9
10 18. Dite GS, Bell R, Reddihough DS, et al. Antenatal and perinatal antecedents of moderate and
11 severe spastic cerebral palsy. *Aust N Z J Obstet Gynaecol.* 1998;38:377-83.
12
13
14
15 19. Blair E, Stanley F. When can cerebral palsy be prevented? The generation of causal hypotheses
16 by multivariate analysis of a case-control study. *Paediatr Perinat Epidemiol.* 1993;7:272-301.
17
18
19
20 20. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in
21 epidemiology. *Eur J Epidemiol.* 2014;29:541-9.
22
23
24
25
26 21. Kristensen J, Langhoff-Roos J, Skovgaard LT, et al. Validation of the Danish Birth
27 Registration. *J Clin Epidemiol.* 1996;49:893-7.
28
29
30
31
32 22. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull.* 1998;45:320-3.
33
34
35
36 23. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public*
37 *Health.* 2011;39:30-3.
38
39
40
41 24. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable
42 source of data for modern health sciences. *Dan Med Bull.* 1999;46:263-8.
43
44
45
46 25. Topp M, Langhoff-Roos J, Uldall P. Validation of a cerebral palsy register. *J Clin Epidemiol.*
47 1997;50:1017-23.
48
49
50
51
52 26. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify
53 gross motor function in children with cerebral palsy. *Dev Med Child Neurol.* 1997;39:214-23.
54
55
56
57
58
59
60

- 1
2
3
4 27. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of
5 competing risks: new representations of old estimators. *Stat Med*. 1999;18:695-706.
6
7
8
9
10 28. Piekkala P, Kero P, Sillanpaa M, et al. Growth and development of infants surviving respiratory
11 distress syndrome: a 2-year follow-up. *Pediatrics*. 1987;79:529-37.
12
13
14
15 29. Patrianakos-Hoobler AI, Msall ME, Marks JD, et al. Risk factors affecting school readiness in
16 premature infants with respiratory distress syndrome. *Pediatrics*. 2009;124:258-67.
17
18
19
20
21 30. Hirvonen M, Ojala R, Korhonen P, et al. Cerebral palsy among children born moderately and
22 late preterm. *Pediatrics*. 2014;134:e1584-93.
23
24
25
26 31. Thygesen SK, Olsen M, Christian FC. Positive predictive value of the infant respiratory distress
27 syndrome diagnosis in the Danish National Patient Registry. *Clin Epidemiol*. 2013;5:295-8.
28
29
30
31 32. Sukhov A, Wu Y, Xing G, et al. Risk factors associated with cerebral palsy in preterm infants. *J*
32 *Matern -Fetal Neonatal Med*. 2012;25:53-7.
33
34
35
36 33. Topp M, Langhoff-Roos J, Uldall P. Preterm birth and cerebral palsy. Predictive value of
37 pregnancy complications, mode of delivery, and Apgar scores. *Acta Obstet Gynecol Scand*.
38 1997;76:843-8.
39
40
41
42 34. Harcke Jr. HT, Naeye RL, Storch A, et al. Perinatal cerebral intraventricular hemorrhage. *J*
43 *Pediatr*. 1972;80:37-42.
44
45
46
47 35. Berg B. Neurology of the Newborn, 4th Edition, by J.J. Volpe. *Muscle Nerve*. 2001;24:1099-
48
49
50
51 36. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at
52 Risk for Late Preterm Delivery. *N Engl J Med*. 2016;374:1311-20.
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legend:**
5

6 **Figure 1.** Cumulative incidence of cerebral palsy in 24,728 children with and without infant
7 respiratory distress syndrome (IRDS) in Denmark during 1997-2003.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of 39,420 infants born during 32–36 weeks of gestation with and without infant respiratory distress syndrome (IRDS), between January 1, 1997 and December 31, 2007 in Denmark.

	IRDS, n (%)	No IRDS, n (%)
All	2,255 (100.0)	37,165 (100.0)
Gestational age (week of gestation)		
32	602 (26.7)	2,058 (5.5)
33	545 (24.2)	3,313 (8.9)
34	526 (23.3)	5,652 (15.2)
35	346 (15.3)	9,156 (24.6)
36	236 (10.5)	16,986 (45.7)
Birth year		
1997-1999	534 (23.7)	9,379 (25.2)
2000-2002	602 (26.7)	10,443 (28.1)
2003-2005	696 (30.9)	10,433 (28.1)
2006-2007	423 (18.8)	6,910 (18.6)
Gender		
Female	897 (39.8)	17,184 (46.2)
Male	1,358 (60.2)	19,981 (53.8)
Apgar score at 5 minutes		
Low (0-6)	111 (4.9)	646 (1.7)
Intermediate (7-8)	271 (12.0)	1,824 (4.9)
Normal (9-10)	1,816 (80.5)	33,974 (91.4)
Missing	57 (2.5)	721 (1.9)
Multiplicity		
Singleton	1,644 (72.9)	27,438 (73.8)
Twin	611 (27.1)	9,727 (26.2)
Epilepsy		
	53 (2.4)	590 (1.6)
Major malformation (<1 year)		
	217 (9.6)	2,525 (6.8)
Mother's age at delivery		
<18 years	5 (0.2)	130 (0.4)
18-34 years	1,807 (80.1)	30,131 (81.1)
≥35 years	443 (19.7)	6,903 (18.6)
Missing	0 (0.0)	1 (0.0)
Maternal smoking status		

Non Smoker/former smoker	1,689 (74.9)	26,487 (71.3)
Smoker	403 (17.9)	8,433 (22.7)
Missing	163 (7.2)	2,245 (6.0)
Bronchopulmonary dysplasia (BPD) (<1 year)		
Yes	22 (1.0)	16 (0.1)
Intracerebral/intraventricular hemorrhage (ICH/IVH) (<30 days)		
Yes	46 (2.0)	121 (0.3)
Necrotizing enterocolitis (NEC) (<30 days)		
Yes	20 (0.9)	59 (0.2)
Patent ductus arteriosus (PDA) (<30 days)		
Yes	77 (3.4)	239 (0.6)
Other diseases*		
Yes	682 (30.2)	6,641 (17.9)

*Other diseases whose symptoms may overlap with those of IRDS, occurring within 4 days of birth (perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and bacterial infections).

Table 2. Hazard ratios of cerebral palsy (CP) by age 8 among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark. (N=39,410)

	Number of children with CP		8-year cumulative incidence, % (95% confidence interval (CI))		Crude hazard ratio (95% CI)	Adjusted hazard ratio* (95% CI)
	Children with IRDS	Children without IRDS	Children with IRDS	Children without IRDS		
Overall	42	178	1.9 (1.4-2.5)	0.5 (0.4-0.6)	4.0 (2.9-5.6)	2.0 (1.4-2.9)
Gestational age						
32 weeks of gestation	21	31	3.5 (2.2-5.2)	1.5 (1.1-2.1)	2.3 (1.3-4.0)	2.4 (1.4-4.2)
33 weeks of gestation	11	44	2.0 (1.1-3.5)	1.3 (1.0-1.7)	1.6 (0.8-3.1)	1.6 (0.8-3.1)
34 weeks of gestation	7	30	1.4 (0.6-2.7)	0.5 (0.4-0.8)	2.5 (1.1-5.8)	2.5 (1.1-5.8)
[35-36] weeks of gestation	3	73	0.5 (0.1-1.4)	0.3 (0.2-0.4)	1.9 (0.6-6.1)	1.7 (0.5-5.5)
Calendar year						
[1997-2002]	28	105	2.5 (1.7-3.5)	0.5 (0.4-0.6)	4.8 (3.2-7.3)	2.4 (1.5-3.7)
[2003-2007]	14	73	1.3 (0.7-2.1)	0.4 (0.3-0.5)	3.1 (1.7-5.4)	1.4 (0.8-2.6)
Gender						
Female	14	76	1.6 (0.9-2.6)	0.4 (0.4-0.6)	3.6 (2.1-6.4)	1.7 (0.9-3.1)
Male	28	102	2.1 (1.4-3.0)	0.5 (0.4-0.6)	4.2 (2.7-6.3)	2.2 (1.4-3.4)
Apgar score at 5 minutes						
Low (0-6)	4	10	3.7 (1.2-8.5)	1.6 (0.8-2.8)	2.1 (0.7-6.8)	2.2 (0.7-7.7)
Intermediate (7-8)	7	31	2.6 (1.2-5.0)	1.7 (1.2-2.4)	1.6 (0.7-3.5)	1.2 (0.5-2.8)
Normal (9-10)	28	131	1.6 (1.1-2.2)	0.4 (0.3-0.5)	4.1 (2.7-6.2)	1.9 (1.2-2.9)
Missing	3	6	5.3 (1.4-13)	0.8 (0.4-1.8)	6.6 (1.6-26)	6.0 (1.0-35)
Multiplicity						
Singleton	29	129	1.8 (1.2-2.5)	0.5 (0.4-0.6)	3.9 (2.6-5.8)	2.0 (1.3-3.1)
Twin	13	49	2.1 (1.2-3.5)	0.5 (0.4-0.7)	4.3 (2.3-7.9)	1.9 (1.0-3.6)

Maternal age						
Younger than 35 years of age	31	138	1.7 (1.2-2.4)	0.5 (0.4-0.5)	3.9 (2.6-5.7)	1.9 (1.3-2.9)
35 years of age or older	11	40	2.5 (1.3-4.3)	0.6 (0.4-0.8)	4.4 (2.3-8.6)	2.3 (1.1-4.8)

*Adjusted for sex, gestational age, infant's birth year, multiplicity, major malformations, and maternal age.

For peer review only

Table 3. Hazard ratios of cerebral palsy (CP) among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark.

	Number of children with CP		Crude hazard ratio (95% CI)*	Adjusted hazard ratio (95% CI)
	Children with IRDS	Children without IRDS		
Selected sub-types†				
Unilateral spastic CP	12	74	2.7 (1.5-5.0)	1.5 (0.8-2.9)
Bilateral spastic CP	26	87	5.1 (3.3-7.9)	2.2 (1.4-3.4)
Motor Handicap [1997-2003]‡				
GMFCS§ 1-2	16	71	4.0 (2.3-6.8)	2.2 (1.3-3.9)
GMFCS 3	1	4	4.4 (0.5-39)	2.2 (0.2-21)
GMFCS 4-5	4	70	6.1 (3.3-11)	2.5 (1.3-4.7)
Developmental Quotient (DQ)¶				
DQ <50	11	33	5.6 (2.8-11)	2.9 (1.4-6.1)
DQ 50-85	14	60	3.9 (2.2-7.0)	1.7 (0.9-3.1)
DQ >85	17	80	3.6 (2.1-6.1)	1.9 (1.1-3.4)

*Confidence interval

†Only selected sub-types are included

‡The covariate is only valid in 1997-2003 and had missing information for 2 CP cases

§Gross Motor Function Classification Skills

¶The DQ covariate had missing data for 5 CP cases. Of note, we did complete case analysis




Figure 1. Cumulative incidence of cerebral palsy in 24,728 children with and without infant respiratory distress syndrome (IRDS) in Denmark during 1997-2003.

(Figure A)

55x40mm (300 x 300 DPI)

Appendix A. ICD-10 diagnoses codes used in the study retrieved from the Danish National Patient Registry.

	ICD-10 diagnosis code (1994-2009)
Idiopathic respiratory distress syndrome/hyaline membrane disease	DP220+DP22A
Cerebral palsy	DG80, DG81, DG82, DG83
Major malformations <1 year	Q00-99
Complications:	
Bronchopulmonary dysplasia <1 year	DP271
Intraventricular hemorrhage or cerebral leukomalaci <30 days	DB100-DP109
Necrotizing enterocolitis <30 days	DP52 + DP912
Patent ductus arteriosus <30 days	DP77
Other diseases (<4 days after birth date):	
Perinatal breathing disorders and cardiovascular diseases	DP221, DP228, DP229, DP23-DP26, DP28-DP29
Congenital virus infection	DP35
Bacterial infection in newborns	DP36
Infection in the central nervous system (CNS)	DG00-DG09
Pneumonia	DJ12-DJ18

STROBE Statement—We hereby confirm that our manuscript, entitled, “Respiratory distress syndrome in preterm infants and risk of cerebral palsy: A population-based cohort study” complies with the STROBE guidelines for the reporting of observational studies. Below we have inserted a “Page number” column to indicate where the STROBE Item number has been incorporated into our paper.

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	6-8
		(e) Describe any sensitivity analyses	9

Continued on next page

Results			Page Number
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11
		(b) Indicate number of participants with missing data for each variable of interest	24-25
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-11, 26-28
		(b) Report category boundaries when continuous variables were categorized	10-11, 24-25
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10, 26-28
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12, 28
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15-16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Respiratory distress syndrome in moderately late and late preterm Infants and risk of cerebral palsy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011643.R3
Article Type:	Research
Date Submitted by the Author:	09-Sep-2016
Complete List of Authors:	Thygesen, Sandra; Aarhus Universitetshospital, Department of Clinical Epidemiology Olsen, Morten; Aarhus University, Department of Clinical Epidemiology Ostergaard, John; Aarhus Universitetshospital, Department of Pediatrics Sørensen, Henrik T.; Aarhus University Hospital, Department of Clinical Epidemiology; Stanford University, Departments of Health Research and Policy (Epidemiology)
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Paediatrics, Neurology, Respiratory medicine
Keywords:	EPIDEMIOLGY, respiratory distress syndrome, cerebral palsy, neurodevelopmental disorder, cohort study, PERINATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Respiratory distress syndrome in moderately late and late preterm infants and risk of**
5
6 **cerebral palsy: A population-based cohort study**
7
8

9 Sandra Kruchov Thygesen, Morten Olsen, John R. Østergaard, Henrik Toft Sørensen
10

11
12 **Affiliations:**
13

14
15 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
16 Denmark
17 Sandra Kruchov Thygesen
18 MD
19

20
21 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
22 Denmark
23 Morten Olsen
24 Associate professor

25
26 Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200 Aarhus N,
27 Denmark
28 John R Østergaard
29 Professor

30
31 Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N,
32 Denmark and
33 Departments of Health Research and Policy (Epidemiology), Stanford University, 259 Campus Drive,
34 Stanford, CA 94305, United States
35 Henrik Toft Sørensen
36 Professor

37
38 **Keywords:** Epidemiology, cohort study, pediatrics, neurology, pulmonary medicine

39
40 **Corresponding Author:** Sandra Kruchov Thygesen, st@clin.au.dk, phone: + 45 8716 8063

41
42 **Word count:** abstract 300 + article 2,845

43
44 **Number of figures:** 1

45
46 **Number of tables:** 3

47
48 **Number of supplementary file:** 1 (appendix)

49
50 **Number of references:** 36
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Infant respiratory distress syndrome (IRDS) is a known risk factor for intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia. These lesions are known to increase the risk of cerebral palsy (CP). Thus, we wanted to examine the long-term risk of CP following IRDS in moderately late and late preterm infants.

Design: Population-based cohort study.

Setting: All hospitals in Denmark.

Participants: We used nationwide medical registries to identify a cohort of all moderately and late preterm infants (defined as birth during 32-36 full gestational weeks) born in Denmark in 1997-2007 with and without hospital diagnosed IRDS.

Main outcomes measures: We followed study subjects from birth until first diagnosis of CP, emigration, death, or end of follow-up in 2014. We computed the cumulative incidence of CP before age 8 years and used Cox's regression analysis to compute hazard ratios of IRDS, comparing children with IRDS to those without. Hazard ratios were adjusted for multiple covariates.

Results: We identified 39,420 moderately late and late preterm infants, of whom 2,255 (5.7%) had IRDS. The cumulative incidence of CP was 1.9% in infants with IRDS and 0.5% in the comparison cohort. The adjusted hazard ratio of CP was 2.0 [95% confidence interval (CI): 1.4-2.9]. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS accompanied by a diagnosis of ICH/IVH. After restriction to children without diagnoses of perinatal breathing disorders other than IRDS, congenital heart disease and viral or bacterial infections occurring within 4 days of birth, the overall adjusted hazard ratio was 2.1 (95% CI: 1.4-3.1).

1
2
3
4 **Conclusion:** The risk of CP was increased in moderately late and late preterm infants with IRDS
5
6 compared to infants without IRDS born during the same gestational weeks.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- A strength of this study includes the nationwide cohort study design with virtually complete follow-up, minimizing the risk of selection bias.
- To our knowledge, this is the first study to specifically determine the association between infant respiratory distress syndrome and cerebral palsy utilizing multivariate analysis, and as such, the validity of the estimates presented is unknown.
- Even though this study is one of the largest examining a potential association between infant respiratory distress syndrome and cerebral palsy, it still does not clarify the specific causes leading to increased risk of cerebral palsy.

Introduction

Increasing preterm birth rates over the last few decades have kept the overall incidence of infant respiratory distress syndrome (IRDS) high.¹⁻³ Infant respiratory distress syndrome decreases with increasing gestational age and has a prevalence of about 30% after 32 weeks of gestation.⁴⁻⁶ The condition is caused by lack of surfactant in the lungs, which leads to atelectasis, decreased gas exchange, and hypoxia. Potential complications of IRDS include intracerebral/intraventricular hemorrhage (ICH/IVH) and periventricular leukomalacia (PVL).^{7,8} Studies have reported increased risk of neurodevelopmental impairments, such as neurocognitive and school performance outcomes as well as attention deficit hyperactivity disorder (ADHD) in preterm children with subsequent hypoxic conditions, including IRDS.^{9,10}

Cerebral palsy (CP) is the most common cause of severe disabilities in early childhood.¹¹ The core symptom of CP is disorder of movement and/or posture, but is often accompanied by other neurodevelopmental disorders or sensory problems, such as disturbances of sensation, cognition, communication, perception, behavior and/or seizure disorders.¹² The disorder has a multifactorial and poorly understood etiology. The most important risk factor for CP is preterm birth, observed in about 28%–35% of all children with CP.^{13,14} Major lesions that contribute to CP include ICH/IVH and PVL.^{7,15,16}

Few data exist on the long term prognosis following IRDS. A few case-control studies have reported indications of an association between IRDS and CP.¹⁷⁻¹⁹ However, these studies are limited by small sample sizes and lack of absolute risk estimates. In the present study, we therefore examined the association between IRDS and CP in a nationwide follow-up study of children born moderately and late preterm.

Methods

Setting and data linkage

We conducted this cohort study using population-based medical databases covering the entire country of Denmark. Linkage between databases was possible through the Civil Registration System (CRS), which has kept electronic records of birth date, date of emigration, and date of death since 1968.²⁰ At birth or upon immigration, all Danish residents are assigned a unique Civil Personal Registration (CPR) number that is used in all public Danish registries. The Danish National Health Service provides free tax-supported health care to the country's 5.6 million citizens.

Study Cohort

Our cohort was identified using the Danish Medical Birth Registry, which contains information on all births in Denmark since 1973. We identified all infants born alive in Denmark from January 1, 1997 to December 31, 2007 (approximately 710,000 infants)^{21, 22} and then restricted our cohort to moderately late and late preterm infants (defined as birth between 32 and 36 full weeks). Adequate representation of children both with and without IRDS is available during these gestational weeks.

Infant respiratory distress syndrome

We identified all children diagnosed with IRDS (exposed children) in the Danish National Patient Registry (DNPR). The DNPR contains data on all non-psychiatric hospital admissions in the country since 1977 and on outpatient clinic and emergency room visits since 1995.^{23, 24} Data include dates of admission and discharge, surgical procedure(s) performed, and one primary diagnosis and up to 19 secondary diagnoses coded by the discharging physician according to the *International*

1
2
3
4 *Classification of Diseases, Eighth Edition (ICD-8)* until the end of 1993 and the *Tenth Edition*
5
6 (ICD-10) thereafter.
7
8

9 ***Cerebral palsy***

10
11
12 Children diagnosed with CP were identified from the Danish National Cerebral Palsy Registry
13 (DNCPR). Prerequisites for inclusion in this Registry are a prenatal or perinatal aetiology (events
14 occurring within 28 days of birth.
15
16

17
18
19 All children included in the Registry had their diagnosis externally validated by a child neurologist
20 at the age of 4-5 years, based on review of clinical findings recorded in the medical files. While the
21 Registry includes data on prenatally and perinatally acquired cases of CP since 1950, it became
22 nationwide only in 1995. DNCPR is assumed to cover > 85 % of the children with CP in
23
24 Denmark.²⁵ Registry data include subtype and degree of CP,¹¹ predefined ranges of developmental
25 quotient (DQ: <50, 50-85, >85), motor handicap measured by the Gross Motor Function
26 Classification System (GMFCS, 0-4) (though only complete until birth year 2003), accompanying
27 neurological diseases, and orthopedic surgeries. Results of ultrasound and CT scans of the brain and
28 evaluation of timing of brain damage are available.²⁵ The DQ were mostly based on a clinical
29 evaluation by a neuropsychiatrist, because the results of the psychological assessments were rarely
30 available in the medical files. The GMFCS is a tool used to measure gross motor skills in children
31 with CP. The classification system ranges from level 1 (walking with no support) up to level 5
32 (immobile/impaired in all areas of motor function).²⁶ We obtained the following study outcomes
33 from the Registry: overall diagnosis of CP, selected subtypes of CP, (unilateral and bilateral spastic
34 CP), motor handicap degree (GMFCS levels 1-2, 3, and 4-5), and DQ (<50, 50-85, and >85).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 ***Covariates***

54
55
56
57
58
59
60

1
2
3
4 We obtained information from the Danish Medical Birth Registry for the entire cohort on
5 gestational age at birth, 5-minute Apgar score, chorioamnionitis, intrauterine growth restriction,
6
7
8 abruptio placenta, multiplicity, maternal age, and self-reported maternal smoking during
9
10 pregnancy.²² Of note, information on administration of antenatal corticosteroids was not available.
11
12 In the early years, weeks of gestation was based on the first day of the last menstrual period. Later,
13
14 prenatal ultrasound measurements were also included as a valid measure for the gestational age.
15
16 However, in the Danish Medical Birth Registry it is not possible to distinguish between the methods
17
18 of measurement used to determine gestational age.²¹ We used data from the DNPR to ascertain the
19
20 distribution of complications in children with and without IRDS, including bronchopulmonary
21
22 dysplasia, ICH/IVH, necrotizing enterocolitis, and patent ductus arteriosus (Appendix A).
23
24
25 Congenital malformations are associated with increased risk of CP and also may be associated with
26
27 IRDS. We therefore ascertained from the DNPR all diagnoses of congenital malformations detected
28
29 during the first year of life.
30
31
32

33
34 A subgroup of children may have had other conditions within 4 days of birth whose symptoms
35
36 potentially overlapped with IRDS, and may potentially lead to misdiagnosis of IRDS. These
37
38 diseases include perinatal breathing disorders other than IRDS, congenital heart diseases, and viral
39
40 and bacterial infections. We identified these conditions from the DNPR. (Appendix A)
41
42

43 *Statistical analysis*

44
45
46 We followed all children in the study cohort from date of birth until the date of the first diagnosis of
47
48 CP, emigration, death, or December 31, 2014, whichever came first. We computed the cumulative
49
50 incidence of CP before 8 years of age with death as a competing risk.²⁷ In a sub-analysis, the
51
52 commonest sub-types of CP were analyzed as separate outcomes (unilateral and bilateral spastic
53
54
55
56
57
58
59
60

1
2
3
4 CP), as well as motor handicap degree (GMFCS 1-2, 3, and 4-5) (only valid until birth year 2003),
5
6 and developmental quotient (<50, 50-85, and >85).
7
8

9
10 We used Cox proportional hazard regression to estimate unadjusted and adjusted hazard ratios
11 (HRs) for CP among children with IRDS compared to children without IRDS. The analyses were
12 adjusted for gestational age (32, 33, 34, 35, and 36 weeks of gestation), birth year (1997-1999,
13 2000-2002, 2003-2005, and 2006-2007), gender, multiplicity (singleton/twins), major
14 malformations, and maternal age (<35 and \geq 35 years of age). The assumptions of proportional
15 hazards were all verified graphically. We considered a low 5-minute Apgar score as a causal
16 intermediate step between IRDS and CP, and thus did not include this covariate as a confounder in
17 the adjusted analyses. However, we did include 5-minute Apgar score in the regression model in a
18 sub-analysis. Chorioamnionitis, intrauterine growth restriction, and abruptio placenta are important
19 independent risk factors of CP. Moreover, these conditions are associated with IRDS, not
20 independently, but through low gestational age. Though, they did not qualify as confounders in the
21 association between IRDS and CP, we did include the three covariates as confounders in a sub-
22 analysis.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 We stratified the analyses on gestational age (birth at 32, 33, 34, and 35-36 full weeks), birth year
40 (1997-2002, 2003-2007), gender, multiplicity, 5-minute Apgar score (0-6, 7-8, 9-10, missing), and
41 maternal age (<35 and \geq 35 years of age) and calculated 95% confidence intervals (CIs).
42
43
44

45 Intracerebral/intraventricular hemorrhage is a known complication of IRDS and an important risk
46 factor for CP. We therefore repeated the analyses for children with IRDS *and* a diagnosis of
47 ICH/IVH within 30 days of birth compared to children with IRDS *and no* diagnosis of ICH/IVH. Of
48 note, cranial ultrasound is not performed as a routine in moderately late and late preterm infants, so
49 the proportion of infants with a diagnosis of ICH/IVH is based on detection in only infants selected
50 for neuroimaging based on clinical presentation and risk factors.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Perinatal diseases may be misinterpreted as IRDS because of overlapping clinical symptoms or
5
6 coexist with IRDS. Such perinatal disorders include perinatal breathing disorders other than IRDS,
7
8 congenital heart diseases, and viral and bacterial infections. Thus, in a sensitivity analysis, we
9
10 restricted the IRDS cohort to new-borns *with no* other perinatal disorders occurring within 4 days of
11
12 birth.
13

14
15 All analyses were performed using the STATA 13.1 package (StataCorp LP, College Station, TX,
16
17 USA). According to Danish legislation, registry-based studies do not need permission from an
18
19 ethical board. The study was approved by the Danish Protection Agency (record number: 2014-41-
20
21 3183) and did not require informed consent.
22
23

24 25 ***Patient involvement*** 26

27
28 No patients were involved in setting the research question or the outcome measures, nor were they
29
30 involved in developing plans for design or implementation of the study. No patients were asked to
31
32 advise on interpretation or writing up of results. There are no plans to disseminate the results of the
33
34 research to study participants or the relevant patient community.
35
36

37 38 39 40 41 **Results** 42

43
44 From the Danish Medical Birth Registry, we identified 39,420 children born moderately and late
45
46 preterm between 1997 and 2007. Of these, 2,255 (5.7%) were diagnosed with IRDS. Having
47
48 another perinatal disorder occurring within four days of birth, including perinatal breathing
49
50 disorders other than IRDS, congenital heart diseases, and viral and bacterial infection were more
51
52 prevalent in the children with IRDS (30%) compared to children without IRDS (18%). (Table 1)
53
54
55
56
57
58
59
60

1
2
3
4 The cumulative incidence of CP before 8 years of age was 1.9 (95% CI: 1.4-2.5) in children with
5 IRDS and 0.5 (95% CI: 0.4-0.6) in children without IRDS (Figure 1). The overall crude HR for CP
6 in children with IRDS compared to children without IRDS was 4.0 (95% CI: 2.9-5.6). After
7
8 adjusting for gestational age, birth year, gender, multiplicity, major malformations, and maternal
9
10 age, the HR was 2.0 (95% CI: 1.4-2.9). (Table 2)

11
12
13
14
15
16 When we stratified the analysis by gestational age, we found an increased risk of CP across all
17 strata in children with IRDS compared to children without IRDS. As well, we found no substantial
18 variation in the increased risk of CP in children with IRDS across categories of gender, year of
19 birth, multiplicity, 5-minute Apgar score, and maternal age, although these estimates were less
20 precise. The adjusted HR of CP was 12 (95% CI: 4.5-34) in children with IRDS complicated by a
21 discharge diagnosis of ICH/IVH.
22
23
24
25
26
27
28
29

30 Including 5-minute Apgar score as a potential confounder in the regression model did not change
31 our estimates substantially. The same was evident, when we included chorioamnionitis, intrauterine
32 growth restriction, and abruptio placenta as potential confounders in the regression analysis (overall
33 HR of 2.0 (95% CI: 1.4-2.9)). When restricting to children diagnosed with IRDS *and no* other
34 relevant coexisting diagnoses occurring within 4 days of birth (i.e. perinatal breathing disorders
35 other than IRDS, congenital heart diseases, and viral and bacterial infections), the overall adjusted
36 HR was 2.1 (95% CI: 1.4-3.1).
37
38
39
40
41
42
43
44
45

46 The most common subtype of CP was unilateral and bilateral spastic CP. (Data not shown) For
47 children diagnosed with IRDS, we found a HR of 1.5 (95% CI: 0.8-2.9) for unilateral spastic CP
48 and 2.2 (95% CI: 1.4-3.4) for bilateral spastic CP. The HR was 1.9 (95% CI: 1.1-3.4) for CP with a
49 normal DQ (above 85), 1.7 (95% CI: 0.9-3.1) for a DQ between 50 and 85, and 2.9 (95% CI: 1.4-
50 6.1) for a DQ below 50. (Table 3)
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In children with IRDS born during 1997-2003, the HR was 2.2 (95% CI: 1.3-3.9) for a mild degree
5
6 of motor handicap (GMFCS 1-2) and 2.5 (95% CI: 1.3-4.7) for a severe degree of motor handicap
7
8 (GMFCS 4-5). (Table 3)
9

10 11 12 13 14 **Discussion**

15
16
17 We found an increased risk of CP associated with IRDS in children born moderately late and late
18
19 preterm.
20

21
22
23 Other studies have shown increased risk of neurodevelopmental impairments, defined by
24
25 psychomotor development and school readiness, in preterm children with IRDS.^{9, 10, 28, 29} Studies
26
27 have looked at possible causes or predictors of cerebral palsy in different settings and found modest
28
29 associations. In an Australian case-control study, Blair et al. reported an odds ratio of CP of 2.3
30
31 (95% CI: 1.3-4.3); and in another case-control study from Western Australia, Dite et al. found an
32
33 odds ratio of 9.4 (95% CI: 1.8-48) in children diagnosed with IRDS. However; even though they
34
35 reported increased risk estimates of CP in children with IRDS, the estimates were based on
36
37 univariate analyses in relatively small study populations. Thus, potential confounders were not
38
39 taken into consideration and no absolute measures were available.¹⁷⁻¹⁹ In a cohort study, Hirvonen
40
41 et al. found a negative association between IRDS and CP in late preterm infants. However,
42
43 apparently the multivariate model included intermediate steps between IRDS and CP in terms of
44
45 mechanical ventilator treatment and intracranial hemorrhage. Furthermore, the analysis was not
46
47 based on time-to-event methods, but based on logistic regression.³⁰ This may have explained the
48
49 differences between their results and ours.
50
51
52
53

54
55 Through data linkage performed by the Danish Civil Registration System, this population-based
56
57 study had virtually complete follow-up for death, emigration, and hospital admissions, minimizing
58
59
60

1
2
3
4 the risk of selection bias. Because lack of surfactant cannot be measured directly, the diagnosis of
5
6 IRDS is based on the clinical appearance of the infant; thus, it is not possible to make a clear and
7
8 consistent diagnostic test. We previously reported a positive predictive value of 89% (95% CI:
9
10 75%–96%) for children with IRDS born between 32 and 36 weeks of gestation in the DNPR.³¹ In
11
12 this study, IRDS was based exclusively on clinical symptoms, as x-rays were only used infrequently
13
14 early in the study period. Additionally, in a sensitivity analysis, we redefined our exposure of
15
16 children with IRDS to only those having IRDS with no other perinatal disorders occurring within 4
17
18 days of birth. Our estimates were virtually unchanged in this analysis. Because the Cerebral Palsy
19
20 Registry is a clinical database based on specific inclusion criteria including thorough medical record
21
22 review of all children with CP in Denmark, we expect the positive predictive value of the CP
23
24 diagnosis to be close to 100%. A previous validation study of the DNCPR through the DNPR
25
26 reported its completeness to be 85%.²⁵ As any misclassification is not likely associated with IRDS,
27
28 such non-differential bias would eventually lead to an underestimation of the association between
29
30 IRDS and CP.
31
32
33
34
35

36 One of the strongest risk factors for development of CP is known to be low gestational age,^{32,33}
37
38 which is also the strongest risk factor for IRDS. For this reason, we stratified our analyses on
39
40 gestational age to ensure that any increased risk of CP in children with IRDS was not masked by
41
42 this association. After taking this precaution, we still found an increased risk of CP among children
43
44 born during gestational weeks 32 to 34. Only a few children diagnosed with CP were born during
45
46 35 and 36 weeks of gestation, which made calculations of the HR imprecise.
47
48
49

50 To study rare disease like CP large study populations are required, especially when the study
51
52 sample is restricted to children born at 32-36 gestational weeks. For this reason, we were only able
53
54 to present overall estimates in our analyses of selected subtypes of CP, degree of motor handicap,
55
56 and DQ. These estimates were all increased throughout all levels of CP severity. Of note, the
57
58
59
60

1
2
3
4 prespecified DQ score category, including scores of 50-85, encompassed both children with normal
5
6 intelligence as well as delayed children, indicating a diverse group. Thus, not too much emphasis
7
8 should be given to this group.
9

10
11 Even though this study is among the largest studies examining a potential association between
12
13 IRDS and CP by using data from nationwide databases on preterm infants, it still does not clarify
14
15 the specific causes of the increased risk of CP. We found a twelve-fold increase of CP in children
16
17 with IRDS and a diagnosis of ICH/IVH compared to our control population. This may suggest an
18
19 important role of ICH/IVH in the pathogenesis, though this is only speculations.^{15, 34, 35} In
20
21 moderately late and late preterm infants, neuroimaging is not routinely performed, indicating that
22
23 some of these children may have an undiagnosed ICH/IVH. Based on this, the proportion of
24
25 children with ICH/IVH may have been underestimated in both the exposed group as well as the
26
27 comparison cohort, making the HR imprecise.
28
29
30

31
32 Antenatal corticosteroids decrease the risk of IRDS, as well as ICH/IVH. However, recent studies
33
34 have reported adverse neurodevelopment outcomes in children receiving antenatal steroids.³⁶ We
35
36 did not have information of treatment with antenatal corticosteroids, which is a limitation of our
37
38 study.
39

40
41 Infant respiratory distress syndrome potentially could be a surrogate for another unknown medical
42
43 condition. However, recognition of an early predictor of increased future CP risk could still be
44
45 helpful when planning follow-up and/or intervention strategies in children born preterm.
46
47
48

49 50 51 52 53 **Conclusion** 54 55 56 57 58 59 60

1
2
3
4 We found that the risk of CP was twice as high in moderately late and late preterm infants with
5
6 IRDS compared to infants without IRDS born during the same gestational weeks.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-011643 on 11 October 2016. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 **Copyright Licence:** The Corresponding Author has the right to grant on behalf of all authors and
5 does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

perpetuity, in all forms, formats and media (whether known now or created in the future), to i)
publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
other languages, create adaptations, reprints, include within collections and create summaries,
extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the
Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic
links from the Contribution to third party material where-ever it may be located; and, vi) licence
any third party to do any or all of the above.

Contributor's Statement: SKT conceptualized and designed the study, acquired the data, carried
out the analyses, drafted the initial manuscript, reviewed and revised the manuscript, and approved
the final manuscript as submitted. MO, JRO, and HTS conceptualized and designed the study,
supervised the data interpretation, critically reviewed and revised the manuscript for important
intellectual content, and approved the final manuscript as submitted. MO helped to acquire the data
and extract the raw data, critically supervised/reviewed the data analyses and reviewed the data
interpretation, revised the manuscript, and approved the final manuscript as submitted.

Funding: This study was supported by grants from the Clinical Epidemiological Research
Foundation ('Klinisk Epidemiologisk Forskningsfond'), Denmark (HTS), and the Program for
Clinical Research Infrastructure (PROCRIN) established by the Lundbeck and the Novo Nordisk
Foundations (HTS). The funding agencies had no role in the design of the study; the collection,

1
2
3
4 analysis, and interpretation of the data; the writing of the article; or the decision to submit the article
5
6 for publication.
7
8
9

10
11
12 **Competing risk declaration:** All authors have completed the Unified Competing Interest form at
13 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
14
15 declare: no support from any organisation for the submitted work; no financial relationships with
16
17 any organisations that might have an interest in the submitted work in the previous three years, and
18
19 no other relationships or activities that could appear to have influenced the submitted work
20
21
22
23
24
25
26

27 **Ethical approval:** Not needed.
28
29
30
31
32

33 **Author Statement:** All authors, external and internal, had full access to all of the data (including
34
35 statistical reports and tables) in the study and can take responsibility for the integrity of the data and
36
37 the accuracy of the data analysis.
38
39
40
41
42

43 **Transparency declaration:** SKT affirms that the study hypothesis arose before inspection of the
44
45 data and that the manuscript is an honest, accurate, and transparent account of the study being
46
47 reported; that no important aspects of the study have been omitted; and that any discrepancies from
48
49 the study as planned have been explained.
50
51
52
53
54
55

56 **Data sharing:** No additional data available.
57
58
59
60

References

1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet*. 2012;379:2162-72.
2. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. *Lancet*. 2008;371:75-84.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet*. 2008;371:261-9.
4. Robertson PA, Sniderman SH, Laros RK, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. *Am J Obstet Gynecol*. 1992;166:1629,41; discussion 1641-5.
5. Koivisto M, Marttila R, Kurkinen-Raty M, et al. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990s: a population-based survey. *Acta Paediatr*. 2004;93:177-84.
6. Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. *Biol Neonate*. 1998;74:7-15.
7. Kinney HC. The Near-Term (Late Preterm) Human Brain and Risk for Periventricular Leukomalacia: A Review. *Semin Perinatol*. 2006;30:81-8.

- 1
2
3
4 8. Sun H, Xu F, Xiong H, et al. Characteristics of respiratory distress syndrome in infants of
5
6 different gestational ages. *Lung*. 2013;191:425-33.
7
8
- 9
10 9. McGrath MM, Sullivan MC, Lester BM, et al. Longitudinal Neurologic Follow-Up in Neonatal
11
12 Intensive Care Unit Survivors with Various Neonatal Morbidities. *Pediatrics*. 2000;106:1397.
13
14
- 15 10. Getahun D, Rhoads GG, Demissie K, et al. In utero exposure to ischemic-hypoxic conditions
16
17 and attention-deficit/hyperactivity disorder. *Pediatrics*. 2013;131:e53-61.
18
19
- 20 11. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a
21
22 collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe
23
24 (SCPE). *Dev Med Child Neurol*. 2000;42:816-24.
25
26
- 27 12. Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral
28
29 palsy, April 2005. *Dev Med Child Neurol*. 2005;47:571-6.
30
31
- 32 13. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of
33
34 genetic variants. *Am J Obstet Gynecol*. 2015;.
35
36
- 37 14. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. *Best Pract Res Clin Obstet*
38
39 *Gynaecol*. 2004;18:425-36.
40
41
- 42 15. Futagi Y, Toribe Y, Ogawa K, et al. Neurodevelopmental Outcome in Children With
43
44 Intraventricular Hemorrhage. *Pediatr Neurol*. 2006;34:219-24.
45
46
- 47 16. Blair E, Stanley F. Aetiological pathways to spastic cerebral palsy. *Paediatr Perinat Epidemiol*.
48
49 1993;7:302-17.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Stelmach T, Pisarev H, Talvik T. Ante- and perinatal factors for cerebral palsy: case-control
5 study in Estonia. *J Child Neurol*. 2005;20:654-60.
6
7
8
9
10 18. Dite GS, Bell R, Reddihough DS, et al. Antenatal and perinatal antecedents of moderate and
11 severe spastic cerebral palsy. *Aust N Z J Obstet Gynaecol*. 1998;38:377-83.
12
13
14
15 19. Blair E, Stanley F. When can cerebral palsy be prevented? The generation of causal hypotheses
16 by multivariate analysis of a case-control study. *Paediatr Perinat Epidemiol*. 1993;7:272-301.
17
18
19
20 20. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in
21 epidemiology. *Eur J Epidemiol*. 2014;29:541-9.
22
23
24
25
26 21. Kristensen J, Langhoff-Roos J, Skovgaard LT, et al. Validation of the Danish Birth
27 Registration. *J Clin Epidemiol*. 1996;49:893-7.
28
29
30
31
32 22. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull*. 1998;45:320-3.
33
34
35
36 23. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public*
37 *Health*. 2011;39:30-3.
38
39
40
41 24. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable
42 source of data for modern health sciences. *Dan Med Bull*. 1999;46:263-8.
43
44
45
46 25. Topp M, Langhoff-Roos J, Uldall P. Validation of a cerebral palsy register. *J Clin Epidemiol*.
47 1997;50:1017-23.
48
49
50
51
52 26. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify
53 gross motor function in children with cerebral palsy. *Dev Med Child Neurol*. 1997;39:214-23.
54
55
56
57
58
59
60

- 1
2
3
4 27. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of
5 competing risks: new representations of old estimators. *Stat Med*. 1999;18:695-706.
6
7
8
9
10 28. Piekkala P, Kero P, Sillanpaa M, et al. Growth and development of infants surviving respiratory
11 distress syndrome: a 2-year follow-up. *Pediatrics*. 1987;79:529-37.
12
13
14
15 29. Patrianakos-Hoobler AI, Msall ME, Marks JD, et al. Risk factors affecting school readiness in
16 premature infants with respiratory distress syndrome. *Pediatrics*. 2009;124:258-67.
17
18
19
20
21 30. Hirvonen M, Ojala R, Korhonen P, et al. Cerebral palsy among children born moderately and
22 late preterm. *Pediatrics*. 2014;134:e1584-93.
23
24
25
26 31. Thygesen SK, Olsen M, Christian FC. Positive predictive value of the infant respiratory distress
27 syndrome diagnosis in the Danish National Patient Registry. *Clin Epidemiol*. 2013;5:295-8.
28
29
30
31
32 32. Sukhov A, Wu Y, Xing G, et al. Risk factors associated with cerebral palsy in preterm infants. *J*
33 *Matern -Fetal Neonatal Med*. 2012;25:53-7.
34
35
36
37 33. Topp M, Langhoff-Roos J, Uldall P. Preterm birth and cerebral palsy. Predictive value of
38 pregnancy complications, mode of delivery, and Apgar scores. *Acta Obstet Gynecol Scand*.
39 1997;76:843-8.
40
41
42
43
44 34. Harcke Jr. HT, Naeye RL, Storch A, et al. Perinatal cerebral intraventricular hemorrhage. *J*
45 *Pediatr*. 1972;80:37-42.
46
47
48
49
50 35. Berg B. Neurology of the Newborn, 4th Edition, by J.J. Volpe. *Muscle Nerve*. 2001;24:1099-
51
52
53
54 36. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at
55 Risk for Late Preterm Delivery. *N Engl J Med*. 2016;374:1311-20.
56
57
58
59
60

1
2
3
4 **Figure legend:**
5

6 **Figure 1.** Cumulative incidence of cerebral palsy in 24,728 children with and without infant
7 respiratory distress syndrome (IRDS) in Denmark during 1997-2003.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of 39,420 infants born during 32–36 weeks of gestation with and without infant respiratory distress syndrome (IRDS), between January 1, 1997 and December 31, 2007 in Denmark.

	IRDS, n (%)	No IRDS, n (%)
All	2,255 (100.0)	37,165 (100.0)
Gestational age (week of gestation)		
32	602 (26.7)	2,058 (5.5)
33	545 (24.2)	3,313 (8.9)
34	526 (23.3)	5,652 (15.2)
35	346 (15.3)	9,156 (24.6)
36	236 (10.5)	16,986 (45.7)
Birth year		
1997-1999	534 (23.7)	9,379 (25.2)
2000-2002	602 (26.7)	10,443 (28.1)
2003-2005	696 (30.9)	10,433 (28.1)
2006-2007	423 (18.8)	6,910 (18.6)
Gender		
Female	897 (39.8)	17,184 (46.2)
Male	1,358 (60.2)	19,981 (53.8)
Apgar score at 5 minutes		
Low (0-6)	111 (4.9)	646 (1.7)
Intermediate (7-8)	271 (12.0)	1,824 (4.9)
Normal (9-10)	1,816 (80.5)	33,974 (91.4)
Missing	57 (2.5)	721 (1.9)
Multiplicity		
Singleton	1,644 (72.9)	27,438 (73.8)
Twin	611 (27.1)	9,727 (26.2)
Epilepsy		
	53 (2.4)	590 (1.6)
Major malformation (<1 year)		
	217 (9.6)	2,525 (6.8)
Mother's age at delivery		
<18 years	5 (0.2)	130 (0.4)
18-34 years	1,807 (80.1)	30,131 (81.1)
≥35 years	443 (19.7)	6,903 (18.6)
Missing	0 (0.0)	1 (0.0)
Maternal smoking status		

Non Smoker/former smoker	1,689 (74.9)	26,487 (71.3)
Smoker	403 (17.9)	8,433 (22.7)
Missing	163 (7.2)	2,245 (6.0)
Bronchopulmonary dysplasia (BPD) (<1 year)		
Yes	22 (1.0)	16 (0.1)
Intracerebral/intraventricular hemorrhage (ICH/IVH) (<30 days) †		
Yes	46 (2.0)	121 (0.3)
Necrotizing enterocolitis (NEC) (<30 days)		
Yes	20 (0.9)	59 (0.2)
Patent ductus arteriosus (PDA) (<30 days)		
Yes	77 (3.4)	239 (0.6)
Other diseases*		
Yes	682 (30.2)	6,641 (17.9)

*Other diseases whose symptoms may overlap with those of IRDS, occurring within 4 days of birth (perinatal breathing disorders other than IRDS, congenital heart diseases, and viral and bacterial infections).

†Information on total number of infants undergoing cranial ultrasound examination is unavailable.

Table 2. Hazard ratios of cerebral palsy (CP) by age 8 among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark. (N=39,410)

	Number of children with CP		8-year cumulative incidence, % (95% confidence interval (CI))		Crude hazard ratio (95% CI)	Adjusted hazard ratio* (95% CI)
	Children with IRDS	Children without IRDS	Children with IRDS	Children without IRDS		
Overall	42	178	1.9 (1.4-2.5)	0.5 (0.4-0.6)	4.0 (2.9-5.6)	2.0 (1.4-2.9)
Gestational age						
32 weeks of gestation	21	31	3.5 (2.2-5.2)	1.5 (1.1-2.1)	2.3 (1.3-4.0)	2.4 (1.4-4.2)
33 weeks of gestation	11	44	2.0 (1.1-3.5)	1.3 (1.0-1.7)	1.6 (0.8-3.1)	1.6 (0.8-3.1)
34 weeks of gestation	7	30	1.4 (0.6-2.7)	0.5 (0.4-0.8)	2.5 (1.1-5.8)	2.5 (1.1-5.8)
[35-36] weeks of gestation	3	73	0.5 (0.1-1.4)	0.3 (0.2-0.4)	1.9 (0.6-6.1)	1.7 (0.5-5.5)
Calendar year						
[1997-2002]	28	105	2.5 (1.7-3.5)	0.5 (0.4-0.6)	4.8 (3.2-7.3)	2.4 (1.5-3.7)
[2003-2007]	14	73	1.3 (0.7-2.1)	0.4 (0.3-0.5)	3.1 (1.7-5.4)	1.4 (0.8-2.6)
Gender						
Female	14	76	1.6 (0.9-2.6)	0.4 (0.4-0.6)	3.6 (2.1-6.4)	1.7 (0.9-3.1)
Male	28	102	2.1 (1.4-3.0)	0.5 (0.4-0.6)	4.2 (2.7-6.3)	2.2 (1.4-3.4)
Apgar score at 5 minutes						
Low (0-6)	4	10	3.7 (1.2-8.5)	1.6 (0.8-2.8)	2.1 (0.7-6.8)	2.2 (0.7-7.7)
Intermediate (7-8)	7	31	2.6 (1.2-5.0)	1.7 (1.2-2.4)	1.6 (0.7-3.5)	1.2 (0.5-2.8)
Normal (9-10)	28	131	1.6 (1.1-2.2)	0.4 (0.3-0.5)	4.1 (2.7-6.2)	1.9 (1.2-2.9)
Missing	3	6	5.3 (1.4-13)	0.8 (0.4-1.8)	6.6 (1.6-26)	6.0 (1.0-35)
Multiplicity						
Singleton	29	129	1.8 (1.2-2.5)	0.5 (0.4-0.6)	3.9 (2.6-5.8)	2.0 (1.3-3.1)
Twin	13	49	2.1 (1.2-3.5)	0.5 (0.4-0.7)	4.3 (2.3-7.9)	1.9 (1.0-3.6)

Maternal age						
Younger than 35 years of age	31	138	1.7 (1.2-2.4)	0.5 (0.4-0.5)	3.9 (2.6-5.7)	1.9 (1.3-2.9)
35 years of age or older	11	40	2.5 (1.3-4.3)	0.6 (0.4-0.8)	4.4 (2.3-8.6)	2.3 (1.1-4.8)

*Adjusted for sex, gestational age, infant's birth year, multiplicity, major malformations, and maternal age.

For peer review only

Table 3. Hazard ratios of cerebral palsy (CP) among children with and without infant respiratory distress syndrome (IRDS) born during 32–36 weeks of gestation between 1992 and 2007 in Denmark.

	Number of children with CP		Crude hazard ratio (95% CI)*	Adjusted hazard ratio (95% CI)
	Children with IRDS	Children without IRDS		
Selected sub-types†				
Unilateral spastic CP	12	74	2.7 (1.5-5.0)	1.5 (0.8-2.9)
Bilateral spastic CP	26	87	5.1 (3.3-7.9)	2.2 (1.4-3.4)
Motor Handicap [1997-2003]‡				
GMFCS§ 1-2	16	71	4.0 (2.3-6.8)	2.2 (1.3-3.9)
GMFCS 3	1	4	4.4 (0.5-39)	2.2 (0.2-21)
GMFCS 4-5	4	70	6.1 (3.3-11)	2.5 (1.3-4.7)
Developmental Quotient (DQ)¶				
DQ <50	11	33	5.6 (2.8-11)	2.9 (1.4-6.1)
DQ 50-85	14	60	3.9 (2.2-7.0)	1.7 (0.9-3.1)
DQ >85	17	80	3.6 (2.1-6.1)	1.9 (1.1-3.4)

*Confidence interval

†Only selected sub-types are included

‡The covariate is only valid in 1997-2003 and had missing information for 2 CP cases

§Gross Motor Function Classification Skills

¶The DQ covariate had missing data for 5 CP cases. Of note, we did complete case analysis




Figure 1. Cumulative incidence of cerebral palsy in 24,728 children with and without infant respiratory distress syndrome (IRDS) in Denmark during 1997-2003.

(Figure A)

55x40mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Appendix A.** ICD-10 diagnoses codes used in the study retrieved from the Danish National Patient Registry.

	ICD-10 diagnosis code (1994-2009)
Idiopathic respiratory distress syndrome/hyaline membrane disease	DP220+DP22A
Cerebral palsy	DG80, DG81, DG82, DG83
Major malformations <1 year	Q00-99
Complications:	
Bronchopulmonary dysplasia <1 year	DP271
Intraventricular hemorrhage or cerebral leukomalaci <30 days	DB100-DP109
Necrotizing enterocolitis <30 days	DP52 + DP912
Patent ductus arteriosus <30 days	DP77
Other diseases (<4 days after birth date):	
Perinatal breathing disorders and cardiovascular diseases	DP221, DP228, DP229, DP23-DP26, DP28-DP29
Congenital virus infection	DP35
Bacterial infection in newborns	DP36
Infection in the central nervous system (CNS)	DG00-DG09
Pneumonia	DJ12-DJ18

STROBE Statement—We hereby confirm that our manuscript, entitled, “Respiratory distress syndrome in preterm infants and risk of cerebral palsy: A population-based cohort study” complies with the STROBE guidelines for the reporting of observational studies. Below we have inserted a “Page number” column to indicate where the STROBE Item number has been incorporated into our paper.

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	6-8
		(e) Describe any sensitivity analyses	9

Continued on next page

Results			Page Number
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11
		(b) Indicate number of participants with missing data for each variable of interest	24-25
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-11, 26-28
		(b) Report category boundaries when continuous variables were categorized	10-11, 24-25
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10, 26-28
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12, 28
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15-16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.